

PCT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C. 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 09 October 2000 (09.10.00)	
International application No. PCT/CA00/00201	Applicant's or agent's file reference KB/12987.6
International filing date (day/month/year) 24 February 2000 (24.02.00)	Priority date (day/month/year) 24 February 1999 (24.02.99)
Applicant CRINE, Philippe et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

06 September 2000 (06.09.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<p>The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer</p> <p>Manu Berrod</p> <p>Telephone No.: (41-22) 338.83.38</p>
--	--

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT
OR THE DECLARATION

(PCT Rule 44.1)

To:

GOUDREAU GAGE DUBUC
The Stock Exchange Tower
Attn. DUBUC, J.
800 Place Victoria, Suite 3400
Montréal, Quebec. H4Z 1E9
CANADA

Date of mailing
(day/month/year)

20/02/2001

Applicant's or agent's file reference

KB/12987.6

FOR FURTHER ACTION

See paragraphs 1 and 4 below

International application No.

PCT/CA 00/ 00201

International filing date

(day/month/year)

24/02/2000

Applicant

UNIVERSITE DE MONTREAL et al.

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ **With regard to the protest** against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Chantal Meyer

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference KB/12987.6	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/CA 00/ 00201	International filing date (day/month/year) 24/02/2000	(Earliest) Priority Date (day/month/year) 24/02/1999
Applicant UNIVERSITE DE MONTREAL et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 6 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.



the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :



contained in the international application in written form.



filed together with the international application in computer readable form.



furnished subsequently to this Authority in written form.



furnished subsequently to this Authority in computer readable form.



the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.



the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☒ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,



the text is approved as submitted by the applicant.



the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,



the text is approved as submitted by the applicant.



the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.



as suggested by the applicant.



because the applicant failed to suggest a figure.



because this figure better characterizes the invention.

1



None of the figures.

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N9/64 C12N15/57 C12N5/10 C07K16/40 A61K38/48
A61K48/00 A61K39/395 G01N33/53

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, PAJ, WPI Data, MEDLINE, SCISEARCH, BIOTECHNOLOGY ABS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 10078 A (HENDERSON JANET E ;KARAPLIS ANDREW C (CA); LIPMAN MARK L (CA); SHE) 12 March 1998 (1998-03-12) the whole document --- -/--	1-34

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

5 February 2001

Date of mailing of the international search report

20 2 01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

ALCONADA RODRIG., A

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>LIPMAN MARK L ET AL: "Cloning of human PEX cDNA: Expression, subcellular localization, and endopeptidase activity" JOURNAL OF BIOLOGICAL CHEMISTRY, US, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 273, no. 22, 29 May 1998 (1998-05-29), pages 13729-13737, XP002134628 ISSN: 0021-9258 page 13731, left-hand column, last paragraph -right-hand column, paragraph 4 page 13734, left-hand column, paragraph 3 -page 13735, right-hand column, paragraph 2 figures 2,7,8</p>	1-13,20, 21,35-40
Y	<p>DEVAULT A ET AL: "EXPRESSION OF NEUTRAL ENDOPEPTIDASE ENKEPHALINASE IN HETEROLOGOUS COS-1 CELLS CHARACTERIZATION OF THE RECOMBINANT ENZYME AND EVIDENCE FOR A GLUTAMIC ACID RESIDUE AT THE ACTIVE SITE" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, no. 8, 1988, pages 4033-4040, XP000930009 ISSN: 0021-9258 figures 6,7 page 4036, right-hand column, paragraph 2 -page 4039, right-hand column, paragraph 1</p>	2-5, 13-19, 21-34, 37,40
Y	<p>LEMAY G ET AL: "FUSION OF A CLEAVABLE SIGNAL PEPTIDE TO THE ECTODOMAIN OF NEUTRAL ENDOPEPTIDASE EC 3.4.24.11 RESULTS IN THE SECRETION OF AN ACTIVE ENZYME IN COS-1 CELLS" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 264, no. 26, 1989, pages 15620-15623, XP000929927 ISSN: 0021-9258 cited in the application page 15621, right-hand column, paragraph 2 -page 15622, left-hand column, paragraph 1</p>	1,6-34, 37,40

-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KORTH PETRA ET AL: "Construction, expression and characterization of a soluble form of human endothelin-converting enzyme-1." FEBS LETTERS, vol. 417, no. 3, 17 November 1997 (1997-11-17), pages 365-370, XP002147123 ISSN: 0014-5793 cited in the application figures 1,4 page 367, left-hand column, paragraph 1 -page 369, left-hand column, paragraph 1 ---	1,6-34, 37,40
Y	HELENE A ET AL: "EFFECTS OF MONOCLONAL ANTIBODIES RAISED AGAINST THE COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN ON ENDOPEPTIDASE-24.11 ACTIVITY" BIOCHEMICAL PHARMACOLOGY, vol. 43, no. 4, 1992, pages 809-814, XP000925844 ISSN: 0006-2952 tables 1-3 page 810, left-hand column, paragraph 2 -right-hand column, last paragraph ---	14-19, 22-27,29
Y	FENTON A J ET AL: "Long-term culture of disaggregated rat osteoclasts: Inhibition of bone resorption and reduction of osteoclast-like cell number by calcitonin and PThrP(107-139)." JOURNAL OF CELLULAR PHYSIOLOGY, vol. 155, no. 1, 1993, pages 1-7, XP000979777 ISSN: 0021-9541 figures 2,5 -----	35,36, 38-40

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-34, 37 (complete) and 40 (partially)

A soluble form of human PHEX; an inactive form of soluble PHEX which still binds ligands consisting on a mutant having glutamic residue at position 582 mutated to valine; a nucleic acid encoding a soluble PHEX in which the transmembrane anchor has been modified to include a cleavable signal peptide, preferably from pro-opiomelanocortin; recombinant vector and host; a method for producing a recombinant soluble PHEX, an antigenic composition, monoclonal or polyclonal antibodies raised against the soluble PHEX, pharmaceutical compositions containing the nucleic acid, the soluble enzyme and the antibody of the invention; diagnostic reagents and kits comprising the anti-PHEX antibody; a method for detecting the presence of PHEX in a sample using the anti-PHEX antibody; a device to purify PHEX using anti-PHEX antibody in which the antibody is fixed to a solid support ; a device to screen PHEX ligands using the soluble PHEX or a mutant thereof in which the the PHEX molecule is fixed to a solid support; a method to obtain a PHEX ligand; a method for evaluating the activity of a molecule for its capacity of being a substrate of PHEX and a kit to carry out said method.

2. Claims: 35, 36, 38, 39 (complete) and 40 (partially)

A method for evaluating PHEX activity in a sample comprising contacting said sample with PTHrp107-139 and observing the appearance of the cleavage product; said method further comprising comparing said PHEX activity with the activity of the soluble PHEX; a method for evaluating the activity of a molecule for its capacity of being a substrate of PHEX comprising contacting said molecule with soluble PHEX and observing a cleavage product of said molecule as an indication that the molecule is a substrate of PHEX, said method further comprising the step of comparing said molecule with PTHrp107-139 as a positive control; a method for evaluating the activity of a molecule for its capacity of being an inhibitor of PHEX comprising contacting said molecule with PTHrp107-139 and soluble PHEX and observing an inhibition of the formation of a cleavage product of PTHrp107-139; a kit for executing any of the previous methods.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA 00/00201

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

Interference on patent family members

National Application No

/CA 00/00201

Patent document
cited in search report

Publication date

Patent family member(s)

Publication
date

WO 9810078

A

12-03-1998

AU

4107397 A


26-03-1998

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



16

Applicant's or agent's file reference KB/12987.6	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/CA00/00201	International filing date (day/month/year) 24/02/2000	Priority date (day/month/year) 24/02/1999
International Patent Classification (IPC) or national classification and IPC C12N9/64		
Applicant UNIVERSITE DE MONTREAL et al.		


- This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
- This REPORT consists of a total of 11 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 6 sheets.

- This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☒ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 06/09/2000	Date of completion of this report 20.06.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Rojo Romeo, E Telephone No. +49 89 2399 7321



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/CA00/00201

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-49 as originally filed

Claims, No.:

1-40 as received on 04/06/2001 with letter of 04/06/2001

Drawings, sheets:

1/8-8/8 as originally filed

Sequence listing part of the description, pages:

1-5, filed with the letter of 09.05.00

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☒ furnished subsequently to this Authority in written form.
- ☒ furnished subsequently to this Authority in computer readable form.
- ☒ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☒ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/CA00/00201

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

5. ☒ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

see separate sheet

6. Additional observations, if necessary:

IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

- ☐ restricted the claims.
☒ paid additional fees.
☐ paid additional fees under protest.
☐ neither restricted nor paid additional fees.

2. ☐ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

- ☐ complied with.
☒ not complied with for the following reasons:
see separate sheet

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

- ☒ all parts.
☐ the parts relating to claims Nos. .

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims 1-40
	No: Claims

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/CA00/00201

Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-40
Industrial applicability (IA)	Yes:	Claims	1-40
	No:	Claims	

2. Citations and explanations
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

Re Item I

Basis of this report

Concerning the following comments, the Applicant's arguments were carefully considered but were not found to be convincing.

Concerning claim 2, no basis could be found for "a PHEX signal peptide/transmembrane region" in the application as filed (see e.g. pages 18, 19, PHEX membrane anchor, not signal peptide). Consequently, claim 2 and dependent claims do not comply with Rule 70(2) PCT.

In the interest of the Applicant, the following comment are made as if these features had not been added/changed.

Re Item IV

Lack of unity of invention

The International Preliminary Examination Authority agrees with the objection raised for lack of unity by the International Search Authority.

According to Rule 13 PCT an application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept, i.e. having at least one common technical feature defining a contribution over the known prior art.

Reference is made to the following documents cited in the International Search Report:
D1: WO 98 10078 A (HENDERSON JANET E ;KARAPLIS ANDREW C (CA); LIPMAN MARK L (CA); SHE) 12 March 1998 (1998-03-12)

The original set of claims was found to concern 2 groups of inventions:

invention 1 (claims 1-34, 37-39, entirely; 40, partially)

a soluble form of human PHEX; an inactive form of soluble PHEX which still binds ligands consisting on a mutant having glutamic residue at position 582 mutated to valine; a nucleic acid encoding a soluble PHEX in which the transmembrane anchor has been modified to include a cleavable signal peptide, preferably, from pro-opiomelanocortin; a recombinant vector and host; a method for producing a recombinant soluble PHEX, an antigenic composition, monoclonal or polyclonal antibodies raised against the soluble PHEX, pharmaceutical compositions containing the nucleic acid, the soluble enzyme and the

antibody of the invention; diagnostic reagents and kits comprising the anti-PHEX antibody; a method for detecting the presence of PHEX in a sample using the anti-PHEX antibody; a device to purify PHEX using anti-PHEX antibody in which the antibody is fixed to a solid support; a device to screen PHEX ligands using the soluble PHEX or a mutant thereof in which the PHEX molecule is fixed to a solid support; a method to obtain a PHEX ligand; a method for evaluating the activity of a molecule for its capacity of being a substrate of PHEX; a method for evaluating the activity of a molecule for its capacity of being an inhibitor of PHEX comprising contacting said molecule with PTHrp107-139 and soluble PHEX and observing an inhibition of the formation of a cleavage product of PTHrp107-139; a kit for executing any of the previous methods.

invention 2 (claims 35, 36, entirely; 40, partially)

A method for evaluating PHEX activity in a sample comprising contacting said sample with PTHrp107-139 and observing the appearance of the cleavage product; said method further comprising comparing said PHEX activity with the activity of the soluble PHEX as positive control; a kit for executing any of the previous method.

The inventions as defined above relate to a human PHEX polypeptide. The common concept of the present application relates to a human PHEX polypeptide.

A human PHEX polypeptide is known in Fig. 1 and 2 of D1.

in the light of the prior art, the following problems and their corresponding solutions could be identified in the present application:

first problem:

Provision of a soluble form of human PHEX. The solution is the replacement of the stop-transfer signal by the signal peptide of pro-opiomelanocortin.

Second problem:

Provision of a method to evaluate the activity of human PHEX. The solution is the use of the PTHrp107-139 as a substrate for the PHEX endopeptidase activity.

Due to the fact that the human PHEX enzyme is known from prior art, due to the fact the mutants of invention 1 and the proteolytic substrate of invention 2 are not structurally

related, and due to the fact that no other technical feature can be distinguished which, in the light of the prior art, could be regarded as a special technical feature in the sense of Rule 13.2 PCT, there is no single general inventive concept underlying the plurality of claimed inventions of the present application in the sense of Rule 13.1 PCT.

The Applicant's attention is drawn to the fact that the first group of inventions might be split in the regional phase, into as many independent inventions as there are variants of the PHEX protein.

Since the Applicant payed an additional examination fee, both groups of inventions are examined here.

The Applicant's attention is drawn to the fact that, due to the reorganization of the claims in the set submitted with Applicant's letter of 04.06.01, the claims are distributed as follows: invention 1 (claims 1-34, 35, 36, 39, entirely; 40, partially)

invention 2 (claims 37, 38, entirely; 40, partially)

Indeed, the technical feature: " pure enzymatically active soluble PHEX" is not present in claims 37 and 38 and 40 (partially).

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following documents cited in the International Search Report:

- D2: LIPMAN MARK L ET AL: 'Cloning of human PEX cDNA: Expression, subcellular localization, and endopeptidase activity' JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 273, no. 22, 29 May 1998 (1998-05-29), pages 13729-13737, XP002134628 ISSN: 0021-9258
- D3: DEVAULT A ET AL: 'EXPRESSION OF NEUTRAL ENDOPEPTIDASE ENKEPHALINASE IN HETEROLOGOUS COS-1 CELLS CHARACTERIZATION OF THE RECOMBINANT ENZYME AND EVIDENCE FOR A GLUTAMIC ACID RESIDUE AT THE ACTIVE SITE' JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, no. 8, 1988, pages 4033-4040, XP000930009 ISSN: 0021-9258
- D4: LEMAY G ET AL: 'FUSION OF A CLEAVABLE SIGNAL PEPTIDE TO THE

ECTODOMAIN OF NEUTRAL ENDOPEPTIDASE EC 3.4.24.11 RESULTS IN THE SECRETION OF AN ACTIVE ENZYME IN COS-1 CELLS' JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 264, no. 26, 1989, pages 15620-15623, XP000929927 ISSN: 0021-9258 cited in the application

D5: KORTH PETRA ET AL: 'Construction, expression and characterization of a soluble form of human endothelin-converting enzyme-1.' FEBS LETTERS, vol. 417, no. 3, 17 November 1997 (1997-11-17), pages 365-370, XP002147123 ISSN: 0014-5793 cited in the application

D6: FENTON A J ET AL: 'Long-term culture of disaggregated rat osteoclasts: Inhibition of bone resorption and reduction of osteoclast-like cell number by calcitonin and PThrP(107-139).' JOURNAL OF CELLULAR PHYSIOLOGY, vol. 155, no. 1, 1993, pages 1-7, XP000979777 ISSN: 0021-9541

invention 1 (claims 1-34, 35, 36, entirely; 40, partially)

1. Novelty (Art. 33(2) PCT)

An objection for lack of novelty would arise since, in the absence of reference to a nucleotide or amino acid sequence, the claims would be considered to be addressed to any soluble purified human enzyme (see VIII below).

The following comments were made as though reference to a nucleotide or amino acid sequence had been made.

None of the documents cited in the International Search Report discloses the claimed subject-matter. The claims 1-34, 35, 36, entirely; 40, partially are considered novel over these documents as far as they concern invention 1.

2. Inventive step (Art. 33(3) PCT)

D1 and D2 disclose the entire sequence of the PHEX cDNA.

D4 and D5 disclose soluble forms of endopeptidases of the same family by fusing the signal peptide from pro-opiomelanocortin to the ectodomain of the corresponding endopeptidase.

Moreover, as mentioned at page 24 of the present application, two different approaches were used already to transform another membrane-bound class II protein into a soluble form: the fusion of the extracellular domain to a heterologous cleavable signal peptide and changes in the transmembrane domain to transform the

combined signal/anchor into a cleavable signal peptide (lines 3-9).

In addition, as mentioned at page 6 of the present application, there is an extensive sequence and structural similarity between the different members of this peptidase family. Accordingly, the amino acid position in the PHEX protein corresponding to E584 (see D3) used to inactivate other neutral endopeptidases by point mutation (E384V) is at position 582 of the present PHEX protein. These mutants are shown to retain binding capacity.

Consequently, the skilled person would have arrived at the present soluble and/or mutated form of the soluble PHEX protein by combination of the available prior art. Thus, neither the product or its uses is considered to be inventive.

The generation of an antibody against a compound which is not inventive is not inventive either. Moreover, an antibody raised against the entire PHEX is bound to bind to the truncated form of PHEX.

Concerning potential ligands to PHEX, it is indicated in the present application (page 6), that "the same inhibitor can exhibit more than one NEP-like enzyme", "several chemical entities are capable of inhibition of more than one enzyme of the gluzian sub-family".

Claims 1-34, 35, 36, 39, 40 (partially) are therefore not inventive over prior art.

invention 2 (claims 37, 38, entirely; 40, partially)

1. Novelty (Art. 33(2) PCT)

None of the documents cited in the International Search Report discloses the claimed subject-matter. The claims 37, 38, entirely; 40, partially are thus considered novel over these documents as far as they concern invention 2.

2. Inventive step (Art. 33(3) PCT)

D6 discloses that PTH(1-34) and PTHrP(107-139) have antagonistic effects on osteoclast-mediated bone resorption. PTH(1-34) was used in D2 as a substrate to measure PHEX proteolytic activity. Therefore, it would be obvious for the skilled person to test as potential PHEX substrates other PTH related hormones that

regulate bone homeostasis, including agonists and antagonists.

Consequently, claims 37, 38 (entirely) and 40 (partially) are deemed not inventive over prior art.

Re Item VIII

Certain observations on the international application

1. Clarity (Art. 6 PCT)

- 1.1 Concerning claim 1, the Applicant's attention is drawn to the fact that the current set of claims does not refer to a particular sequence to define the term PHEX. In the absence of a reference to a concrete sequence characterizing the PHEX protein or polynucleotide, respectively, said claims lack technical features necessary to clearly define the claimed-subject-matter since the term PHEX has no technical meaning for the person skilled in the art. Consequently, the current set of claims may be interpreted as being directed to any protein or polynucleotide. This applies to the reference to an amino acid position (claims 3-5) without sequence reference, to the signal peptide from pro-opiomelanocortin (claim 7) and to the PTHrP107-139 which is not defined in the claims (35, 36, 38, 39, 40).

This objection applies to the PHEX ectodomain and to the catalytic part of PHEX which are neither defined in technical terms.

Relating to this, the Applicant's attention is drawn to the fact that the claims must be clear without the context of the application.

- 1.2 In addition, the terms "variants" or "mutant thereof" have no technical meaning for the skilled person. The Applicant's attention is drawn to the fact that any protein or nucleic acid can be seen as the "variant" of any other by a certain number or type of modifications, deletions, additions, substitutions, etc. similarly, any protein can be considered to be the mutant of another protein.

Again, the claims must be clear without the context of the application.

- 1.3 Claim 2 does not meet the requirements of Art. 6 PCT in that the matter for which protection is sought is not clearly defined. The claim attempts to define the subject-

matter in terms of the result to be achieved ("modified so as to confer solubility of said PHEX enzyme") which merely amounts to a statement of the underlying problem instead of defining the subject-matter in terms of technical features.

- 1.4 Concerning claim 14, the Applicant's attention is drawn to the fact that a fragment of a protein can be as small as a few amino acids. In this case, an antibody directed against a "fragment of a protein" may recognise other proteins unrelated to PHEX in addition to being able of binding to PHEX.
- 1.5 A device comprising an antibody, without any other technical feature is considered to be a composition comprising said antibody.
- 1.6 Concerning claims 35, 37 and 39 and dependent claims, the term "essentially" phosphate-free is vague (Guideline III-4.5 PCT).

We claim:

1. A soluble purified PHEX enzyme (secPHEX) and variants thereof, comprising a PHEX ectodomain or catalytic part thereof.
2. A soluble purified PHEX enzyme (secPHEX) and variants thereof, comprising a PHEX ectodomain or catalytic part thereof and a PHEX signal peptide/transmembrane region modified so as to confer solubility to said PHEX enzyme when expressed in a eukaryotic host, wherein said host is not a human being.
3. A mutant of the enzyme of claim 1 or 2, which is inactive but retains binding capacity to a ligand molecule to PHEX.
4. A mutant as defined in claim 3 consisting of PHEX enzyme having the glutamic acid residue at position 581 is mutated.
5. A mutant as defined in claim 3 consisting of PHEX enzyme having the glutamic acid residue at position 581 substituted with a hydrophobic amino acid residue.
6. A mutant as defined in claim 3 consisting of PHEX enzyme having the glutamic acid residue at position 581 substituted with a valine residue.
7. A nucleic acid which comprises a truncated PHEX gene sequence encoding PHEX membrane-anchor domain modified to include a cleavable signal peptide and PHEX C-terminal ectodomain is active or inactive.
8. A recombinant vector comprising the nucleic acid of claim 7.

9. A recombinant vector as defined in claim 8, which is an expression vector.
10. A eukaryotic host comprising the recombinant vector of claim 8, wherein said host is not a human being
11. A eukaryotic host comprising the recombinant vector of claim 9, wherein said host is not a human being.
12. A method for producing a soluble PHEX enzyme or an inactive mutant thereof, which comprises the steps of:
 - allowing the eukaryotic host of claim 10 or 11 to express said nucleic acid, and
 - recovering the soluble PHEX enzyme or mutant thereof as a secretion product of said host.
13. An antigenic composition, which comprises the enzyme of any one of claims 1 to 6.
14. An antibody capable of binding to PHEX and raised against the enzyme of any one of claims 1 to 6 or fragment thereof.
15. The antibody of claim 14, wherein said fragment extends from residue 121 to residue 294 of the amino acid sequence of PHEX.
16. An antibody as defined in claim 14, which is a monoclonal antibody.
17. An antibody as defined in claim 15, which is a monoclonal antibody.

18. The antibody of claim 16, which is a PHEX neutralizing antibody.

19. A hybridoma producing the antibody of any one of claims 16 to 18.

20. A composition comprising the enzyme of claim 1 or 2 or the nucleic acid of claim 7 and a pharmaceutically acceptable carrier.

21. A composition comprising the enzyme of any one of claims 3 to 6 and a pharmaceutically acceptable carrier.

22. A composition comprising the antibody of any one of claims 14 to 18 and a pharmaceutically acceptable carrier.

23. A diagnostic reagent for detecting the presence or amount of PHEX, comprising the antibody of any one of claims 14 to 18.

24. A diagnostic kit for detecting the presence or amount of PHEX comprising the antibody of any one of claims 14 to 18.

25. The diagnostic kit of claim 24, which further comprises a soluble PHEX enzyme.

26. A method for detecting the presence or an amount of PHEX in a sample, which comprises the steps of:

- contacting said sample with the antibody of any of any one of claims 14 to 18 in conditions such that the immune complex can form; and
- detecting the immune complexes as an indication of the presence or amount of PHEX in said sample.

27. A device for purifying PHEX or a mutant thereof which comprises the antibody of any one of claims 14 to 18.

28. A device for screening PHEX ligands, which comprises the soluble PHEX enzyme or a mutant thereof as defined in any one of claims 1 to 6.

29. The device of claim 27, wherein said antibody is fixed onto a solid support.

30. The device of claim 28, wherein said PHEX enzyme or mutant is fixed onto a solid support.

31. The device of claim 30, wherein said PHEX enzyme or mutant is fixed onto the solid support through its binding to an anti-PHEX antibody itself fixed onto said solid support.

32. The device of claim 30, wherein said PHEX enzyme or mutant is fixed onto the solid support through a C-terminal amino acid extension ending with a residue or group capable of coupling PHEX to the solid support.

33. A method for obtaining a PHEX ligand which comprising the steps of:

- contacting a sample containing one or more molecules with a PHEX enzyme or mutant as defined in any one of claims 1 to 6 in conditions such that binding of said one or more molecules with PHEX can occur;
- detecting said binding as an indication of the presence of a PHEX ligand in said sample; and

04-00-2001 PCT/CA00/00201
selecting said PHEX ligand.

34. The method of claim 33, wherein said ligand is a PHEX inhibitor or substrate.

35. A method for evaluating the activity of a molecule for its capacity of being a substrate of PHEX comprising the steps of:

- contacting said molecule with the PHEX enzyme of claim 1 in substantially phosphate-free conditions; and
- observing a cleavage product of said molecule as an indication that the molecule is a PHEX substrate.

36. The method of claim 35, which further comprises the step of comparing said molecule with PTHrP107-139 as a positive control.

37. A method for evaluating PHEX activity in a sample which comprises the steps of contacting the sample with a substrate as defined in claim 35 or 36, or preferably with PTHrP107-139, in substantially phosphate-free conditions and observing the apparition of a cleavage product of said substrate or PTHrP107-139 as an indication of PHEX activity in the sample.

38. The method of claim 37, which further comprises a step of comparing said PHEX activity in the sample with the activity of the PHEX enzyme of claim 1 as a positive control.

39. A method for evaluating the activity of a molecule for its capacity of being an inhibitor of PHEX comprising the steps of:

- contacting said molecule with a substrate as defined in claim 35 or 36, or preferably with PTHrP107-139, and the PHEX enzyme of claim 1 in substantially phosphate-free conditions; and

- observing an inhibition of the formation of a cleavage product as an indication that said molecule is a PHEX inhibitor.

40. A kit for executing the method of any one of claims 35 to 39.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 9/64, 15/57, 5/10, C07K 16/40, A61K 38/48, 48/00, 39/395, G01N 33/53	A2	(11) International Publication Number: WO 00/50580 (43) International Publication Date: 31 August 2000 (31.08.00)
--	-----------	---

(21) International Application Number: PCT/CA00/00201 (22) International Filing Date: 24 February 2000 (24.02.00) (30) Priority Data: 2,262,056 24 February 1999 (24.02.99) CA (71) Applicant (for all designated States except US): UNIVERSITE DE MONTREAL [CA/CA]; 2900 boulevard Edouard-Montpetit, Montreal, Quebec H3C 3J7 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): CRINE, Philippe [CA/CA]; 28 Avenue Claude-Champagne, Outremont, Quebec H2V 2X1 (CA). BOILEAU, Guy [CA/CA]; 7645 Malherbe, Brossard, Quebec J4Y 1E6 (CA). (74) Agents: DUBUC, Jean, H. et al.; Goudreau Gage Dubuc, The Stock Exchange Tower, Suite 3400, 800 Place Victoria, Montreal, Quebec H4Z 1E9 (CA).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
--	--

(54) Title: COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX

(57) Abstract

This invention relates to a soluble form of PHEX, PHEX being a type II integral membrane glycoprotein. This enzyme is the gene product of a phosphate-regulating gene with homologies to endopeptidases on the X chromosome. To produce a soluble form of PHEX, the transmembrane anchor domain has been modified to encode a signal peptidase coding sequence. The soluble PHEX therefore comprises the active ectodomain. An inactive mutant of PHEX is also an object of this invention. Both soluble and inactive mutant forms of PHEX can be used to screen ligands to PHEX. These ligands can also be used as substrates or inhibitors of PHEX. PHEX being phosphaturic, an inhibitor thereof will be used to treat phosphaturia and/or hypophosphatemia. On the opposite, a substrate for PHEX or PHEX itself can be used to treat hyperphosphatemia.

Cytosolic (19 aa) Transmembr. (20 aa) Ectodomain

NH₂ 1

POMC S.P.

2

A

VGGTLVLGTLILFLVSQGLLS 1

VLTVIAQQTTLFLVSQGLLS 2

VLTVIAQOTT SQGLLS 3

B

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF THE INVENTION

Composition, Methods and Reagents for the Synthesis of a Soluble Form of Human PHEX

BACKGROUND OF THE INVENTION

The PHEX gene (formerly PEX; Phosphate regulating gene with homologies to Endopeptidases on the X chromosome) was identified by a positional cloning approach as the candidate gene for X-linked hypophosphatemia (XLH) (Francis et al., 1995). XLH is a Mendelian disorder of phosphate homeostasis characterized by growth retardation, rachitic and osteomalacic bone disease, hypophosphatemia, and renal defects in phosphate re-absorption and vitamin D metabolism (Rasmussen and Tenenhouse, 1995). Using the information made available by the publication of the sequence of the PHEX gene, and standard techniques obvious to those skilled in the art, several groups have cloned and sequenced the human and mouse PHEX/Phex cDNAs (Du et al., 1996; Lipman et al., 1998; Grieff et al., 1997; Beck et al., 1997; Guo and Quarles, 1997; Strom et al., 1997) (PHEX/Phex refers to the human and mouse genes, respectively). Amino acid sequence comparisons have demonstrated homologies between PHEX/Phex protein and members of the neutral endopeptidase family as previously observed in the partial sequence of the candidate gene (Francis et al., 1995). The peptidases of the neutral endopeptidase family are zinc-containing type II integral membrane glycoproteins with a relatively short cytoplasmic N-terminal region, a single transmembrane domain, and a long extracytoplasmic domain, which contains the active site of the enzyme (Devault et al., 1987).

The mechanism by which loss of PHEX function elicits the bone and renal abnormalities observed in XLH patients is not clear. There are no data suggesting the presence of PHEX/Phex mRNA in the kidney (Du et al., 1996; Beck et al., 1997; Grieff et al., 1997). The increased renal phosphate excretion in Hyp mice is due to a down-regulation of the phosphate transporter, which is necessary for the re-absorption of the phosphate from the nephron (Tenenhouse 1998). The serum concentration of $1,25(\text{OH})_2\text{D}_3$ (calcitriol) was found to be the same in Hyp mice as in normal littermates (Meyer 1980). However, the Hyp kidney showed an accelerated degradation of the vitamin D metabolite to $1,24,25(\text{OH})_3\text{D}_3$, a metabolite with reduced activities (Tenenhouse 1988). In the presence of a phosphate rich diet, Hyp mice experienced an increase in serum $1,25(\text{OH})_2\text{D}_3$ and a fall in the C-24 oxidation products, while normal mice experienced no such changes (Tenenhouse 1990). To summarize, the renal disorder in vitamin D metabolism in Hyp mice appears to be secondary to the phosphate disorder.

PHEX/Phex mRNA was detected in bones by Northern blot hybridization and in other adult and fetal tissues such as lungs, liver, muscles, and ovaries by RT-PCR and RNase protection assays (Du et al., 1996; Beck et al., 1997). *In situ* hybridization performed on sections of embryos and newborn mice showed the presence of Phex mRNA in osteoblasts and odontoblasts (Ruchon et al., 1998). Phex gene expression was detectable on day 15 of embryonic development, which coincides with the beginning of intracellular matrix deposition in bones. Moreover, Northern analysis of total RNA from calvariae and teeth of 3-day-old and adult mice showed that the abundance of the Phex transcript is decreased in adult bones and in non growing teeth. This result was confirmed when the presence of the Phex protein in newborn adult bones

was investigated by Western blotting using a monoclonal antibody raised against the human PHEX. Immunohistochemical studies on a 2 month-old mouse showed exclusive labelling of mature osteoblasts and osteocytes in bones and of odontoblasts in teeth (Ruchon et al., 2000: J Bone Miner. Res. In press). Taken together these results suggest that PHEX/Phex plays an important role in the development and maintenance of mineralization in these tissues.

Further insights into the role of PHEX in bone metabolism were provided by experimental studies on cases of oncogenic osteomalacia (OOM), a tumor-associated sporadic condition with very similar clinical indications. There is strong evidence that a tumor-produced humoral factor inhibits renal phosphate re-absorption and vitamin D synthesis resulting in osteomalacia (Nelson et al., 1997). Experimental studies on Hyp and Gy mice, the murine model of human XL, also suggest the involvement of a humoral factor. In both mouse models, mutations have been identified in the Phex gene, which also appear to result in loss of function of the gene product (Strom et al., 1997; Beck et al., 1997).

Considering the similarities between PHEX protein and the other members of the metallopeptidase family of enzymes, it has been speculated that PHEX metabolizes a peptide hormone that modulates renal tubular phosphate re-absorption. Such an activity could involve either the processing of a phosphate reabsorbing hormone precursor to its active form or the inactivation of a circulating phosphaturic factor. There is evidence of intrinsic abnormalities in osteoblasts from Hyp mice (Ecarot et al., 1992). A defective phosphate transport was also observed in osteoblasts from Hyp mice (Rifas et al., 1994). PHEX might thus be involved in the control of bone metabolism both indirectly at the level of

the kidney by controlling renal phosphate re-absorption and directly at the level of bones by inactivating a trophic peptide factor controlling either osteoblast or osteoclast functions or both.

Since absence of a functioning PHEX gene leads to hypophosphatemia, it should be possible to control human diseases involving hyperphosphatemia through the inhibition of this enzyme. Thus, inhibiting PHEX will cause a reduction in blood phosphate concentration, allowing for the prevention and reduction of hyperphosphatemia-related disorders in humans and animals. Reduced renal excretion of phosphorus due to impaired kidney functions is the most common cause of hyperphosphatemia. In the specific case of secondary hyperparathyroidism (renal osteodystrophy), proper phosphate concentration would also benefit the patient by leading to an increase in endogenous calcitriol production and/or a lowering of PTH level. Therefore the early and adequate inhibition of PHEX activity could mitigate the serious consequences of renal osteodystrophy, giving patients an opportunity for an improved quality of life without the pain and mobility problems of advanced renal osteodystrophy. Hyperphosphatemia is defined in adults as an elevation of serum phosphorus above 1.67 mmol/L (5 mg/dL). Hyperphosphatemia is a common finding with many causes (Harrison's 14th Ed CD-ROM, McGraw Hill Health Professions Division, New York NY, chapter 356).

Hyperparathyroidism or renal osteodystrophy results from the progressive nature of chronic renal failure. The leading causes of chronic renal failure are diabetes (43%), hypertension (35%) and glomerulonephritis (14%) among US Medicare patients (patients over 65

years of age). (Harrison's 14th Ed CD-ROM, McGraw Hill Health Professions Division, New York NY, chapter 271, Figure 271.1).

Hyperphosphatemia is potentially dangerous because of metastatic calcification. Although only an approximate guide, a calcium-phosphorus product [serum Ca (mg/dL) X serum P (mg/dL)] greater than 70 indicates a potential threat of calcification. Patients with this disease suffer from bone and joint pain, osteopenia, deformities, fractures, muscle weakness and extra-skeletal calcification.

Irrespective of the underlying cause, the disease is characterized by a progressive loss of the kidney ability to eliminate waste, to produce calcitriol (1,25(OH)₂D₃) and to excrete phosphate. Increased phosphate excretion is achieved with elevated PTH.

The direct effect of phosphate on PTH levels is well documented. In the presence of increasing phosphate concentration, intact fresh parathyroid gland showed increased PTH secretion (Almaden, 1996). A high phosphate diet causes elevated PTH while maintaining normal serum phosphate; in contrast, parathyroidectomized rats fed the same diet showed elevated phosphate levels (Borle, 1981 and Demeter 1991). Results in patients with mild to moderate renal failure showed that phosphate concentration correlated directly with PTH (Kates, 1997).

Although the treatment of disorders involving an inappropriate expression of PHEX is a primary goal of the present invention, the opposite is under the scope thereof. Compositions comprising a soluble

active PHEX or a nucleic acid encoding same for the treatment of disorders involving PHEX deficiencies is an object of this invention.

The zinc metallopeptidase family (also known as the Zincins; see Hooper FEBS Letters 354,1-6,1994) is characterized by the presence of a zinc atom at the active site. This large family consists of several sub-classes that can be distinguished by their active site structure. One such sub-family is the gluzincins, which is characterized by the HEXXH motif and a glutamic acid as the third zinc ligand. This sub-family includes thermolysin, ACE (angiotensin converting enzyme), aminopeptidases and enzymes of the Neutral Endopeptidase or Neprilysin (NEP) family. NEP itself is now considered the prototype for the enzymes of the family (Crine 1997). These peptidases share extensive sequence and structural similarities. In addition to NEP, there are five other NEP-like enzymes in the public domain: the endothelin-converting enzymes ECE-1, ECE-2, Kell, XCE and PHEX (for a review, see: Turner and Tazawa, 1997b). Several family members can cleave the same peptide substrates and the same inhibitor can inhibit more than one NEP-like enzyme. In fact, several chemical entities are capable of inhibition of more than one enzyme of the gluzincin sub-family (Roques B. P. Path Biol 1998 46,3,191-200). Therefore, known gluzincins inhibitors can be assayed in a PHEX enzymatic assay and identified as a PHEX inhibitor. Among the methods of this invention is the administration of "PHEX inhibitors". As referred to herein, the term "PHEX inhibitor" includes any compound that inhibits the enzymatic action of PHEX.

SUMMARY OF THE INVENTION

Towards this objective, we have prepared various reagents and tools designed to produce recombinant forms of PHEX and to purify both

the recombinant and native enzymes from cell fractions, spent culture media and tissue extracts. We have cloned a cDNA encoding the full-length human PHEX protein into various expression vectors. These PHEX-encoding vectors were introduced by transfection into various cell lines including COS-1 (monkey kidney) cells, CHO (Chinese Hamster Ovary) cells, and LLC-PK1 (porcine kidney) cells. Permanent cell lines were established and shown to stably express the PHEX protein at the cell surface. A procedure was established to rapidly prepare a membrane fraction enriched in the recombinant PHEX protein.

PHEX is an intrinsic membrane protein anchored by a hydrophobic 20 amino acid sequence located near the N-terminus. The purification of an intrinsic membrane-bound protein requires the use of detergents to free it from the lipidic environment of the membrane. These detergents can interfere with the catalytic activity of the enzyme. Moreover, the detergent-purified proteins usually present stability and solubility problems, especially if concentrated solutions and/or large amounts of the protein are needed, such as those required for crystallization and high throughput screening assays. To facilitate the preparation and purification in high yields of a fully active enzyme, it is thus preferable to work with a soluble form of PHEX. Soluble forms of NEP (Lemay et al., 1989) and ECE (Korth et al., 1997) consisting of the entire ectodomain but lacking the cytosolic and hydrophobic transmembrane domains have been constructed and shown to possess enzymatic activities identical to those of the native membrane-bound homolog. A soluble form of recombinant PHEX was thus constructed by modification of the signal peptide/transmembrane region of the protein. The soluble PHEX comprises PHEX ectodomain or a catalytic part thereof; this soluble form of PHEX is referred to as secPHEX. The expression vector encoding

secPHEX was transfected into LLC-PK1 cells and a permanent cell line expressing the chimeric PHEX protein on a stable basis was established. Analysis of the spent medium of this cell line by Western blot was shown to contain high levels of a secPHEX. This secPHEX was purified using either immunoaffinity or ion exchange chromatography. Ion-exchange chromatography was found to be the most efficient method to purify secPHEX from spent culture medium. The purified secPHEX was shown to be active in an enzymatic assay using PTHrP107-139 as a substrate. Moreover, the availability of this secPHEX rendered possible its use as an antigen for the production of anti-PHEX antibodies.

Monoclonal antibodies specific for PHEX were generated by immunizing mice with a PHEX-derived recombinant fusion protein produced in *E. coli*. These monoclonal antibodies were used to purify recombinant PHEX by various immunoaffinity procedures. PHEX-specific monoclonal antibodies also proved useful for characterizing PHEX expression in bone by immunohistochemical techniques and Western blotting.

The present invention also relates to compositions for treating PHEX-related disorders in humans and animals. The present invention particularly provides compositions for the treatment of hyperphosphatemia, including its most frequent manifestations, secondary hyperparathyroidism and renal osteodystrophy. The compositions comprise an anti-PHEX molecule which, by inhibiting PHEX activity, induce an increase in phosphate excretion as well as a reduction in gut phosphate absorption, thus reducing and/or preferably preventing hyperphosphatemia and the appearance of its most frequent consequences, secondary hyperparathyroidism and renal

osteodystrophy. For example, with such a treatment, normophosphatemia is maintained in patients with mild kidney failure at the expense of PHEX activity as opposed to an increase in PTH serum concentration. While the phenotype resulting from PHEX mutation suggests that PHEX inhibition may be toxic, an attentive study of the physiology suggests otherwise. The dominant nature of the phosphate excretion suggests that only partial inhibition may be required to achieve the desired result. Observations in heterozygous females indicate that an inhibition of much less than 50% is required. At this low level of inhibition, the other features of XLH that are gene-dosage-dependent or phosphate-dependent may not be significant.

Accordingly, a first object of this invention is to provide compositions comprising PHEX enzyme or mutants, or anti-PHEX ligands. These compositions are particularly useful for treating PHEX-related disorders in humans and animals. Further objects include the provision of the following: (1) diagnostic kits for detecting the presence or amount of PHEX in a sample; (2) a method for detecting the presence or amount of PHEX in a sample; (3) devices for purifying PHEX or mutants thereof; (4) devices for screening PHEX ligands; (5) a method for obtaining a PHEX ligand; and (6) enzymatic assays involving PHEX and a PHEX substrate.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS OF THE INVENTION

BRIEF DESCRIPTION OF THE FIGURES

This invention will now be described with reference to the following specific embodiments and drawings, which purpose is to illustrate the invention and not to limit its scope.

Figure 1: Construction of a soluble form of PHEX. Figure 1A (construct 1) represents the schematic structure of the native membrane-bound form of the enzyme and the construct in which the POMC signal peptide has been fused in frame with the ectodomain of the native enzyme (construct 2). Figure 1B represents the construct where part of the sequence for the hydrophobic transmembrane domain in construct 1 (underlined) has been replaced by the more hydrophilic domain in construct 2. In construct 3, part of the hydrophobic sequence has been deleted in addition to insertion of the hydrophilic sequence as in construct 2.

Figure 2: Amino acid sequence of human PHEX. The boxed sequence represents the hydrophobic signal peptide/transmembrane domain. The underlined sequence represents the segment used for making the *E. coli* GST-fusion protein for monoclonal antibody production.

Figure 3: Screening of PHEX monoclonal antibodies. Monoclonal antibodies were first selected for their capacity to bind the PHEX₁₂₁₋₂₉₄ fragment produced in *E. coli* as tested by using the spent medium of hybridoma cultures in ELISA assays. Immunoglobulins from positive cultures were next tested for their ability to bind membrane-bound PHEX from LLC-PK1 cells transfected with the PHEX expression vector. Figure 3A is the Western blot analysis of LLC-PK1 extracts stained with the various hybridoma supernatants. Track 12 is the staining pattern obtained with PHEX polyclonal antibody prepared in rabbit. Figure 3B: immunoprecipitation of a soluble form of PHEX (secPHEX). LLC-PK1

cells were first transfected with a vector encoding a soluble form of PHEX as explained in the Material and Methods section. The spent medium of transfected LLC-PK1 cells was then used as a source of secPHEX for immunoprecipitation experiments. The immunoprecipitation was performed by first saturating protein A-Sepharose beads (Pharmacia) with a rabbit anti-mouse IgG fraction and then with the mouse immunoglobulins from the hybridoma supernatants selected as shown in Figure 3A. After washing, these beads were incubated in aliquots of the spent medium of LLC-PK1 cells producing secPHEX (40 μ g of total protein). The beads were pelleted by centrifugation, washed and the presence of secPHEX was assessed by boiling the proteins bound to protein A-Sepharose in the electrophoresis sample buffer followed by Western blot analysis with a PHEX polyclonal antibody. Track 8 shows the results of an immunoprecipitation done in the same conditions with a rabbit PHEX polyclonal antiserum. Tracks 10 and 11 are control experiments prepared from mock transfected cells.

Figure 4: Expression of membrane-bound and soluble forms of recombinant PHEX in COS-1 cells. COS-1 cells were transfected with expression vectors containing either the entire coding sequence of PHEX (left panel) or a construct capable of promoting the secretion of the PHEX ectodomain (see Methods) (right panel). The cells were kept in culture for 16 h after transfection and either a membrane fraction (left panel) or the spent medium (right panel) was prepared as explained in Methods. The expression of PHEX was monitored in Western blots with monoclonal antibody 15D7. As seen in left panel, a band migrating with a mobility corresponding to an apparent Mr. of 105,000 was present in the membrane fraction of cells transfected with the pCDNA3/RSV-PHEX-FLB vector (lane 2). This band was absent from the extract of control cells

(lane 1). The right panel shows the presence of a secreted soluble form of PHEX in the spent medium of transfected cells, but not in control mock transfected cells.

Figure 5: Ion-exchange chromatography purification of secPHEX. Concentrated spent culture medium from secPHEX expressing LLC-PK1 cells was loaded on SP-Sepharose column and the proteins eluted with a linear NaCl gradient. Fractions were analysed on a 7.5% SDS polyacrylamide gel and detected by immunoblotting (Figure 5A) or by silver staining (Figure 5B).

Figure 6: Enzymatic assay for secPHEX. Purified secPHEX (2 μ g) was incubated

in the presence of 10 μ g PTHrP107-139 and the reaction mixture analyzed by RP-HPLC. Figure 6A shows the chromatogram obtained when PTHrP107-139 is incubated in the absence of secPHEX. Figure 6B shows the digestion of PTHrP107-139 by secPHEX. This degradation can be totally inhibited by the addition of 0.001M EDTA to the reaction mixture (Figure 6C). Cleavage of PTHrP107-139 by secPHEX is sensitive to phosphate concentration (Figure 6D to 6H: 1, 5, 10, 25, 50 mM phosphate, respectively).

In order to provide a clear and consistent understanding of terms used in the present description, a number of definitions are provided hereinbelow. Unless defined otherwise, the scientific and technological terms and nomenclature used herein have the same meaning as commonly understood by a person of ordinary skill to which the present invention pertains.

As used herein, the designation "variant" denotes, in the context of a sequence whether a nucleic acid or amino acid sequence, a molecule that retains a biological activity (either functional or structural) that is substantially similar to that of the original sequence. This variant or equivalent may be a natural intra-species or inter-species variant or may be prepared synthetically. Such variants include amino acid sequences having substitutions, deletions or additions of one or more amino acids, provided that the biological activity of the protein is conserved. The same applies to derivatives of nucleic acid sequences which can have substitutions, deletions or additions of one or more nucleotides, provided that the biological activity of the sequence is generally maintained. When relating to a protein sequence, the substituting amino acid generally has chemico-physical properties which are similar to that of the substituted amino acid. The similar chemico-physical properties include similarities in charge, bulkiness, hydrophobicity, hydrophilicity and the like. The term "variants" is intended to include "fragments", "segments", "functional derivatives", "analogs" or "chemical derivatives" of the subject matter of the present invention.

The term "hydrophobic amino acid residue" is intended to mean an amino acid chosen from the following group: alanine, valine, leucine, isoleucine, proline, methionine, phenylalanine, tryptophan or variants thereof (A. L. Lehninger, Principles of Biochemistry (Worth Publishers, Inc.: 1982), at p.101). In the context of this invention, aliphatic amino acids are preferred.

The expression "anti-PHEX" molecule is intended to mean a molecule such as an "antisense nucleic acid molecule", an "antibody", an

"inhibitor" or an "antagonist" (i.e., any molecule capable of hindering PHEX activity).

The present invention also provides antisense nucleic acid molecules which can be used for example to decrease or abrogate the expression of the nucleic acid sequences or proteins of the present invention. An antisense nucleic acid molecule according to the present invention refers to a molecule capable of forming a stable duplex or triplex with a portion of its targeted nucleic acid sequence (DNA or RNA). The use of antisense nucleic acid molecules and the design and modification of such molecules is well known in the art as described for example in WO 96/32966, WO 96/11266, WO 94/15646, WO 93/08845 and USP 5,593,974. Antisense nucleic acid molecules according to the present invention can be derived from the nucleic acid sequences and modified in accordance to well known methods. For example, some antisense molecules can be designed to be more resistant to degradation to increase their affinity to their targeted sequence, to affect their transport to chosen cell types or cell compartments, and/or to enhance their lipid solubility by using nucleotide analogs and/or substituting chosen chemical fragments thereof, as commonly known in the art.

In general, techniques for preparing antibodies (including monoclonal antibodies and hybridomas) and for detecting antigens using antibodies are well known in the art (Campbell, 1984, In "Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology", Elsevier Science Publisher, Amsterdam, The Netherlands) and in Harlow et al., 1988 (in: Antibody- A Laboratory Manual, CSH Laboratories). The present invention also provides polyclonal, monoclonal antibodies, or humanized versions

thereof, chimeric antibodies and the like which inhibit or neutralize their respective interaction domains and/or are specific thereto.

As commonly known, a "mutation" is a detectable change in the genetic material which can be transmitted to a daughter cell. As well known, a mutation can be, for example, a detectable change in one or more deoxyribonucleotide. For example, nucleotides can be added, deleted, substituted for, inverted, or transposed to a new position. Spontaneous mutations and experimentally induced mutations exist. The result of a mutations of nucleic acid molecule is a mutant nucleic acid molecule. A mutant polypeptide can be encoded from this mutant nucleic acid molecule. A mutation may result in an unaffected mutant, a negatively or positively partially affected mutant, or an inactive mutant. In the embodiment of the present invention, a mutant has been obtained which has the particular capacity to bind to a PHEX but has an inactive catalytic site.

As used herein, the term "purified" refers to a molecule having been separated from a cellular component. Thus, for example, a "purified protein" has been purified to a level not found in nature. A "substantially pure" molecule is a molecule that is lacking in most other cellular components.

As used herein, the terms "molecule" or "ligand" are used interchangeably and broadly to refer to natural, synthetic or semi-synthetic molecules or compounds. The term "molecule" therefore denotes for example chemicals, macromolecules, micromolecules, cell or tissue extracts (from plants or animals) and the like. Non limiting examples of molecules include nucleic acid molecules, peptides, antibodies, carbohydrates and pharmaceutical agents. The agents can be selected and screened by a variety of means including random screening, rational selection and by rational design using for example protein or ligand modelling methods such as computer modelling. The terms "rationally selected" or "rationally designed" are meant to define compounds which have been chosen based on the configuration of interacting domains of the present invention. As will be understood by the person of ordinary skill, macromolecules having non-naturally occurring modifications are also within the scope of the term "molecule". The distinction between a "macro" and a "micro" molecule is made on the basis of size. For example, an oligonucleotide and a peptide having no more than about 100 nucleotides or amino acids, respectively, would be considered micromolecules, whereas a gene, a complete cDNA and a protein would generally be classified as macromolecules because of their larger size. The molecules identified in accordance with the teachings of the present invention have a therapeutic value in diseases or conditions in which the physiology or homeostasis of the cell and/or tissue is compromised by a defect in the nature or level of PHEX gene product. They may also have diagnostic value in the evaluation of the same diseases or conditions.

METHODS

Production of monoclonal antibodies

The cDNA corresponding to amino acids 121 to 294 of the PHEX amino acid sequence (underlined segment in Figure 2) was used to construct a GST-fusion protein in *E. coli*. This fusion protein was purified from *E. coli* extracts by

affinity chromatography on a glutathione-Sepharose column. After thrombin cleavage, the PHEX portion of the GST fusion protein was further purified by electro-elution from a polyacrylamide gel. This material was used to immunize 4 mice (5 injections of $\approx 50 \mu\text{g}$ of PHEX₁₂₁₋₂₉₄). Blood was collected from each mouse after the immunization schedule and the presence of antibodies in mice serum was assessed by ELISA using microtiter plates coated with PHEX₁₂₁₋₂₉₄ from *E. coli* extracts. Mice sera were also tested for the presence of PHEX antibodies by Western blotting extracts of LLC-PK1 cells transfected with the PHEX expression vector. Out of the 4 mice immunized, 3 showed good results both in ELISA and Western blots. One mouse selected for its high titer of PHEX-specific antibodies (as measured by ELISA) was sacrificed and its spleen cells were collected and immortalized by fusion with myeloma cells (strain). Hybridoma cells were selected for their ability to grow in HAT selection medium and cloned by several rounds of limiting dilution.

Expression of human PHEX in transfected cells

A cDNA encoding for the full-length human PHEX was obtained by Polymerase Chain Reaction (PCR) as previously described (Beck et al., 1997). The plasmid pCR2.1-PHEX-FLB was generated by cloning this cDNA into pCR2.1 (Invitrogen). A restriction fragment (SpeI-EcoRV), which contained the entire PHEX coding sequence, was digested, blunted, and subcloned into the mammalian expression vector (pCDNA3/RSV). The resulting plasmid (pCDNA3/RSV-PHEX-FLB) contained the entire PHEX cDNA under the control of the Rous Sarcoma Virus (RSV) promoter.

This recombinant vector was then expressed transiently in COS-1 cells by transfection. COS-1 cells were grown at 37°C under a 5% CO₂ atmosphere in Dulbecco's modified Eagle's medium (DMEM) containing 5% COSMIC (Hyclone), 100 U/ml penicillin, and 100 $\mu\text{g}/\text{ml}$ streptomycin. COS-1 cells were transfected using the calcium phosphate-DNA co-precipitation procedure. The day following

transfection, the serum-containing medium was changed for a synthetic medium that consists of DMEM supplemented with 2.5 µg/ml insulin, 17.5 µg/ml transferrin, 2 µg/ml ethanolamine, 100 µg/ml soybean trypsin inhibitor and 10 µg/ml aprotinin. Finally, sodium butyrate was added to the synthetic medium at a concentration of 10 mM to enhance the expression of the plasmids carrying the RSV promoter. After 48 h, the cells were harvested and the membranes were prepared according to the procedure of Korth et al. (1997).

The plasmid pCDNA3/RSV-PHEX-FLB was also transfected in LLC-PK1 cells by the CaPO_4 precipitation method. Transfected cells were selected by adding 400 µg/ml of G-418 to the culture medium. G-418 resistant cells were grown in 150 mm dishes containing 20 ml medium 199 with Earle's salts, 2mM L-glutamine, Hepes and bicarbonate buffer supplemented with 5% fetal bovine serum (FBS), 50 units/ml penicillin, and 50 µg/ml streptomycin. Cells were grown up to confluence for about a week and harvested by scraping with a rubber policeman.

Construction and expression of a soluble form of recombinant PHEX

To obtain a soluble form of recombinant human PHEX, we first attempted to fuse in frame the cDNA encoding the signal sequence of a secreted protein (pro-opiomelanocortin or POMC) to the cDNA sequence of the ectodomain of human PHEX (Figure 1, panel A). This strategy, which had successfully been used for other members of this family of peptidases, namely NEP and ECE (Lemay et al., 1989; Korth et al., 1997), resulted in the production of a misfolded PHEX protein that remained trapped in the rough endoplasmic of transfected cells. Consequently, an alternate strategy was developed consisting in the substitution of selected amino acids in the N-terminal hydrophobic membrane anchor of PHEX to transform it into a cleavable signal sequence.

Transformation of the membrane anchor into a cleavable signal sequence was carried out on the pCDNA3/RSV/PHEX-FLB plasmid. Site-directed mutations (9 codons) and deletions (4 codons) were introduced by Polymerase Chain Reaction (PCR) amplification using oligonucleotide #5136 as the sense primer 5'CTGACAGTGATCGCTCAACAAACAACCAGTCAAGGTCTCTTAAGTCTCCAAG 3' and oligonucleotide #5134 as the antisense primer 5'GGTTGTTTGTGAGCGATCACTGTCAGGACAAACACGACCAGGGCAATTCG 3' (Figure 1, panel B). The resulting plasmid, designated as pCDNA3/RSV/PHEX-MutE, encoded for a secreted form of PHEX (secPHEX).

This recombinant vector was then expressed transiently in COS-1 cells by transfection as described above. After 16 hours of incubation, the medium was recovered and concentrated by ultrafiltration (MW cut-off = 30 kDa) using a Centriprep cartridge (Amicon). To induce the stable expression of secPHEX in LLC-PK₁ cells, the plasmid pCDNA3/RSV-PHEX-MutE was transfected in LLC-PK₁ cells by the CaPO₄ precipitation method. Transfected cells were selected by adding 400 µg/ml G-418 to the medium. G418 resistant cells were grown in 150 mm dishes containing 20 ml of medium 199 with Earle's salts, 2mM L-glutamine, 1mM sodium pyruvate, Hepes and bicarbonate buffer supplemented with 5% fetal bovine serum (FBS), 100 µg/ml G-418, 50 units/ml penicillin, and 50 µg/ml streptomycin. Cells were grown up to confluence, for about a week. To produce secPHEX, confluent cells were incubated for 4 days in synthetic medium that consists of 199 medium supplemented with 2.5 µg/ml insulin, 17.5 µg/ml transferrin, 2 µg/ml ethanolamine, 100 µg/ml soybean trypsin inhibitor and 10 µg/ml aprotinin. Finally, sodium butyrate was added to the synthetic medium, at a concentration of 10 mM, to enhance the expression of the secPHEX gene, which is under the control of the RSV promoter. After 4 days, the medium was recovered, centrifuged and concentrated by cross-flow filtration (MW cut-off = 30 kDa) using a Sartoclon Micro Unit (Sartorius). Typically, 600 ml of crude spent medium from secPHEX-transfected LLC-PK₁ cells are concentrated to 30 ml before loading on ion-exchange column for purification.

Characterization of secPHEX was done by immunoblotting. Briefly, proteins from the concentrated media were resolved on 7.5% SDS-PAGE, and transferred onto 0.45 μ m nitrocellulose membranes. Membranes were incubated for one hour in TTBS (Tris Buffered Saline containing 0.05% Tween-20) supplemented with 5% (w/v) instant non-fat dry milk (Carnation). Membranes were washed rapidly with TTBS and incubated with a 1:200 dilution of the anti-(human PHEX) monoclonal antibody (13B12) in TTBS supplemented with 1% BSA (w/v). Membranes were washed in TTBS and incubated for one hour with a HRP-labeled second antibody in TTBS supplemented with 1% BSA (w/v). Membranes were washed and processed using a chemiluminescence reagent (NEN).

Other signal peptide coding sequences may be used in so far as they properly govern the secretion of PHEX in the extracellular space (the culture medium or a secretion fluid, depending on the host cell, tissue or organism used).

Immunoprecipitation assay

The immunoprecipitation assay was performed by first saturating protein A-Sepharose beads (Pharmacia) with a rabbit anti-mouse IgG fraction and then with the mouse immunoglobulins from hybridoma supernatants. After washing in PBS, these beads were incubated in aliquots of the spent medium of LLC-PK1 cells producing secPHEX (40 μ g of total protein) diluted in immunoprecipitation (IPP) buffer (20 mM Tris-HCl pH7.4, 100mM NaCl, 2% sodium deoxycholate, 2% Triton X-100, 0.2% SDS, and 0.2% BSA). The beads were pelleted by centrifugation, washed twice in IPP buffer and once in PBS and the presence of secPHEX bound to the immunoaffinity support was assessed by submitting the proteins bound to proteins A Sepharose in a non-covalent fashion to boiling in the electrophoresis sample buffer before immunoblot analysis.

Purification of the soluble form of PHEX

1) Purification of secPHEX by ion-exchange chromatography:

The concentrated medium was loaded on a SP-Sepharose cation-exchange column (Pharmacia) previously equilibrated with 50 mM sodium phosphate pH 6.6 containing 50 mM NaCl. The column was washed with 10 column volumes of the same buffer and SecPHEX was eluted with a 50mM to 1M NaCl gradient. Fractions were analyzed by SDS-PAGE and immunoblotting, as described above, and fractions containing secPHEX visualized by silver staining.

2) Purification of secPHEX by immunoaffinity chromatography

An immunoaffinity column was built by linking antibody 4C5 to Affigel (BioRad). Immunoglobulins were purified from 4C5 ascite on protein G column (Amersham-Pharmacia) and coupled to the Affigel matrix as recommended by the supplier (BioRad). Two mg of IgG were attached to the matrix in a 4 ml column. The column was washed as recommended by the supplier and equilibrated in 20 mM Tris-HCl pH 8.0. An aliquot of 15 ml of concentrated LLC-PK1 culture medium was circulated overnight on the column. The column was washed with 5 volumes of equilibration buffer. The proteins were eluted with 0.1M triethylamine pH 11.5 and immediately neutralized by the addition of 0.2 volume of 1M phosphate buffer pH 6.8. Proteins in fractions were analyzed by SDS-PAGE and immunoblotting.

Preparation of PHEX-containing brush border membranes

The LLC-PK1 cell line forms polarized epithelial monolayers in culture. Brush border (apical) membranes BBMs were purified from LLC-PK1 cell homogenates as described previously (Blais et al., 1987). Briefly, cell membranes were disrupted by sonication. Non-apical membranes were precipitated at 4 °C by adding CaCl_2 to a final concentration of 13 mM under constant agitation. BBMs were fractionated by sequential centrifugation at 950 x g for 10 min and then at 35,000 x g for 30 min. The final pellet containing BBMs was washed twice with 50 mM

Tris-HCl, pH 7.5, and resuspended in the same buffer. The presence of PHEX in BBMs was verified by immunoblotting.

Assay for the activity of PHEX

An aliquot of purified PHEX containing 2 µg of protein was incubated for 15 min at 37 °C in a volume of 200 µl of 50 mM MES (2-(N-Morpholinoethanesulfonic acid, pH 6.5, containing 150 mM NaCl and 10 µg of PTHrP107-139 as a substrate. After the incubation period, the hydrolysis was stopped by the addition of trifluoroacetic acid to a final concentration of 0.1%. Identification of peptide products was performed by reverse phase high performance liquid chromatography (RP-HPLC) on a C18 µBondapak analytical column (Waters) with a UV detector set at 214 nm. Peptides were resolved with a linear gradient of 5% B to 85% B in 45 min at the flow rate of 0.4 ml/min [mobile phase A= 0.1% trifluoroacetic acid; mobile phase B= 80% acetonitrile (CH₃CN), 0.1% trifluoroacetic acid].

RESULTS

Production of monoclonal antibodies

Throughout the limiting dilution process, hybridoma were tested for their ability to bind to PHEX₁₂₁₋₂₉₄ in the ELISA assay, to recognize recombinant full length PHEX in Western blotting assays (Figure 3A) and to immunoprecipitate secPHEX (Figure 3B). Antibody 15D7 showed good results in immunoprecipitation, immunoblotting and also in immunofluorescence experiments (results not shown) and was selected to monitor the expression of PHEX or secPHEX in cultured transfected cells or PHEX in tissues. Other segments of PHEX may be used as antigens provided that they are specific to PHEX in so far as the production of PHEX-specific antibodies is sought.

Expression of membrane-bound recombinant PHEX in COS-1 cells

COS-1 cells were transfected with an expression vector containing the entire coding sequence of PHEX inserted downstream from the RSV promoter. This vector is called pCDNA3/RSV-PHEX-FLB (see Methods). The cells were kept in culture for 16 h after the transfection and a membrane fraction was prepared as explained in Methods. The expression of PHEX was monitored in Western blots with monoclonal antibody 15D7. As seen in Figure 4 a band migrating with a mobility corresponding to an apparent Mr of 105,000 was observed in the membrane fraction of cells transfected with the pCDNA3/RSV-PHEX-FLB vector (lane 2). This band was absent from the extract of control cells (lane 1).

Production of a soluble form of recombinant PHEX

We next wanted to determine whether it is possible to use genetic engineering techniques to promote the secretion of a soluble and active form of PHEX from transfected eukaryotic cells. Obviously, this kind of enzyme, which can easily be purified from the incubation medium of cultured cells without the use of detergent, would be very useful for further structural studies and inhibitor screening. It could also eventually be used as an injectable therapeutic agent or in topical applications to increase the rate of bone mineralization or bone healing.

PHEX is a class II integral membrane protein. Class II membrane proteins have, near their amino terminus, a unique hydrophobic peptide acting both as a signal peptide to direct the translocation of the protein through the membrane of the rough endoplasmic reticulum and as a transmembrane domain for anchoring the protein in the cell plasma membrane. Unlike class I membrane proteins which possess a cleavable signal peptide and are anchored in the membrane by an additional membrane-spanning hydrophobic sequence (also called Stop Transfer Sequence), class II membrane proteins cannot be easily transformed into soluble forms by deleting the hydrophobic transmembrane domain. In class II membrane

proteins, deletion of the anchoring segment also removes the signal peptide, thereby preventing the translocation of the protein in the RER and its transport to the cell surface. Theoretically, there are two different approaches for transforming a membrane-bound class II protein into a soluble form: 1) the extracellular domain of the protein could be fused to a heterologous cleavable signal peptide; and 2) changes in the transmembrane domain could be introduced to transform the combined signal/anchor into a cleavable signal peptide. Both strategies were successfully used to produce a soluble form of NEP (Lemay et al., 1989; Lemire et al., 1997).

In this work, a PHEX secretion vector was first constructed by fusing in-frame the sequence encoding the complete ectodomain of the human enzyme with the POMC signal peptide (Figure 1A), these sequences being under the control of the RSV promoter. Despite the fact that PHEX immunoreactive material could be detected in the cell extract of transfected cells, expression levels were low and no enzyme could be found in the secretion medium (results not shown). When the cell-associated PHEX immunoreactive material was digested with endoglycosidases and analyzed by Western blot, it was found to be essentially endo H sensitive, indicating retention of the recombinant protein in the RER (results not shown).

Replacement of part of the transmembrane region (underlined sequence in Figure 1B: sequence 1) by the underlined sequence shown on line 2 resulted in the secretion of a soluble form of PHEX from transfected COS-1 cells (results not shown). The yield was further increased by deleting the sequence LFLV at the junction between the transmembrane and ectodomain (panel B: sequence 3). Figure 4 (lane 4) shows the amount of recombinant protein secreted in the incubation medium by transfected COS-1 cells. The same vector was also transfected in LLC-PK1 cells as described in Methods and stable transfectants were selected for their G-418 resistance. This pool of G-418 resistant cells was found to secrete substantial amounts of secPHEX (up to 600 µg/L) as seen by

Western blotting (results not shown). SecPHEX was resistant to endo H, indicating that it had acquired terminal sugars, most probably during its transit through the Golgi apparatus (results not shown). The enzyme secreted by cultures of LLC-PK1 cells could then be purified either by immunoaffinity or by ion-exchange chromatography.

Preferred purification of secPHEX by ion-exchange chromatography

Concentrated culture medium from secPHEX-transfected LLC-PK1 cells was loaded on SP-Sepharose column and proteins eluted as described in Methods. Monitoring of the eluate at 280 nm revealed one major protein peak (result not shown), which was shown by immunoblotting to contain secPHEX (Figure 5). Analysis of the fractions containing secPHEX on 7.5% SDS-PAGE and detection of proteins in the gel by silver staining showed that secPHEX represented more than 90% of proteins present in the fractions. Typically, 1.25 mg of pure secPHEX are obtained from 600 ml of non-concentrated culture media.

Although secPHEX has been recovered from spent culture medium, it is feasible nowadays to have a host such as a ruminant, the organs of which are engineered to produce PHEX as a secretion product in milk, for example. A recombinant vector expressible in the tissue could comprise as an insert a construct similar to the one which led to the production of secPHEX in spent culture medium. Modifications to the construct are well known to the skilled artisan (promoter, signal peptide, etc). That recombinant vector is included in a composition and in a method for producing PHEX.

On the opposite, if PHEX needs to be silenced, anti-PHEX molecules are included in the compositions and methods of the present invention and their administration inhibits PHEX activity.

Purification of secPHEX by immunoaffinity

Immunoblot analysis of the fractions obtained from the column showed that secPHEX was retained. However, Coomassie Blue staining showed that other proteins were also present in the fractions (results not shown). The amount of secPHEX obtained from 165 ml of non-concentrated LLC-PK1 culture medium was evaluated at 3 μ g of protein.

Activity of secPHEX

HPLC analysis of PTHrP107-139 digested with secPHEX in conditions described in Methods revealed that secPHEX can degrade this peptide. PTHrP107-139 peak on the chromatogram was decreased to 15% of its original surface after only 15 min of incubation (Figure 6). Peaks corresponding to metabolites appeared on the chromatogram. This enzymatic activity was fully inhibited by 0.001 M EDTA and 0.001 M O-phenantroline, two general inhibitors of metallopeptidases. Activity was also observed in Acetate, HEPES and Tris buffers covering a pH range from 4.0 to 8.5. Phosphate buffer inhibited the activity of the enzyme (Figure 6).

EXAMPLESExample I: Use of recombinant secPHEX to identify its natural substrate in bone

PHEX is expressed in osteoblasts, and its expression is temporally associated with the mineralization of the extracellular matrix in cultured osteoblasts (Beck et al., 1997a; Du et al., 1996a; Guo and Quarles, 1997a) and during development (Ruchon et al., 2000). These observations suggest that bone is a relevant site of PHEX expression and that a potential relationship exists between mutations of PHEX and aberrant osteoblast-mediated mineralization. Thus PHEX may function in osteoblasts to metabolize endogenous or exogenous factors that regulate the process of osteoblast-mediated mineralization. In support of this

hypothesis, a recent report suggests that loss of PHEX function in cultured osteoblasts of Hyp mice is associated with the accumulation of a factor or factors that inhibit mineralization of extracellular matrix *in vitro* (Xiao et al., 1998). The availability of recombinant soluble PHEX greatly facilitates the identification of the physiological bone substrate(s) for PHEX in a series of experiments such as the one described hereunder.

Bones of Hyp mice are dissected, freed from connective tissue, and muscles frozen in liquid nitrogen and lyophilized. The bones are then crushed into a powder and extracted with a strongly acidic solution containing trifluoroacetic acid (TFA), formic acid and 1M NaCl. The composition of this solution is selected such as to inactivate all protease activities and avoid the solubilization of large molecular weight proteins. The acidic extract is then lyophilized and an aliquot containing approximately 100 µg of total peptide resuspended in a physiological buffer at pH around 7.0, is submitted to digestion with 1-10 µg of PHEX purified by ion-exchange or by immunoaffinity chromatography, as described above. A control experiment, where the enzyme preparation is inactivated by acidic or heat treatment prior to the incubation, is conducted in parallel. The peptides contained in the samples are then separated by reversed-phase HPLC on a C18 µBondapak column using buffers containing 0.1% TFA and variable concentrations of acetonitrile (i.e. from 0 to around 80%). The chromatograms of the peptides digested with active or inactivated PHEX are compared. The mixture of bone peptides taken from Hyp mouse and incubated with the inactivated PHEX preparation should contain the PHEX substrate. Incubation of the same mixture with active PHEX however should allow the cleavage of the PHEX substrate into peptide metabolites. Comparison of the chromatograms should thus allow identifying peaks corresponding to PHEX substrate and its metabolites. These peaks are then collected and identified by mass spectrometry and/or automated Edman sequence degradation.

The identification of PHEX substrates may also be done using a similar strategy with conditioned medium taken from cultures of Hyp mouse osteoblasts.

Alternatively, an inactive soluble form of PHEX immobilized on a chromatographic support may be used as an affinity reagent for purifying PHEX substrates from crude extracts of tissues (such as bones) or serum. Cell surface metallopeptidases from the neprilysin family can be modified by the addition of a C-terminal extension without interfering with their enzymatic activity (Howell et al., 1995; Yang et al., 1995). A soluble form of PHEX, extended by an additional C-terminal peptide of approximately 20-25 amino acid residues (called here secPHEX-EC) is constructed by fusing in frame a synthetic oligonucleotide, as explained previously for NEP (Howell et al., 1995). The additional sequence is terminated by a cysteine residue such as to allow its efficient coupling to activated thiol-Sepharose 4B [agarose-(glutathione-2-pyridyl disulfide)] (Pharmacia, Fine Chemicals AB, Uppsala, Sweden). Sec-PHEX-EC is produced in high yields using, for example, the LLC-PK1 cell system used to produce secPHEX. The recombinant protein is purified by ion-exchange or immunoaffinity chromatography using conditions similar to the ones described for the purification of secPHEX. The fractions are analyzed by SDS-PAGE and the purity verified by staining with Coomassie blue.

For binding the purified recombinant protein to the solid phase, the Thiol-Sepharose resin is rehydrated to obtain approximately 1 ml of gel volume. The gel is equilibrated with a buffer A (0.1 M Bis-Tris, 0.5 M NaCl, pH 7.0) and incubated with approximately 3 mg of secPHEX-EC in buffer A (2-4 ml) overnight at 4 °C under constant agitation. The slurry is then washed, first with approximately 1 ml of buffer B (0.1 M Bis-Tris, 5 mM DTT, pH 7.0) and then extensively with buffer A. The quantity of proteins coupled to the support is determined by the Bradford assay (BioRad) on a small amount of gel.

The immobilized secPHEX-EC is used as a solid phase reagent for the screening of PHEX inhibitors. Enzymatically inactive variants of this material is also prepared by binding a form of secPHEX-EC carrying a mutation on the catalytic glutamic acid residue in position 582 to change it into a valine. A similar mutation in the coding sequence of NEP was previously shown to result in a catalytically inactive enzyme that nevertheless retained its full binding activity for inhibitors and substrates (Devault et al., 1988). Such an affinity reagent is used to bind and purify PHEX peptide substrates in crude tissue extracts. Receptors, if any, can be found using the same approach. Screening of inhibitor components can also be performed, although an active PHEX may be preferred. Tissue extracts prepared as described above are incubated under constant agitation in a buffer such as 0.1M Bis-Tris pH 7.5 with 1 ml of the affinity resin at 4°C. After washing in the same binding buffer, the bound peptides can be eluted from the gel by either raising or lowering the pH and/or by increasing the ionic strength of the buffer. Many other mutations may be envisaged, the purpose of which remains the replacement or elimination of the glutamic acid residue which is specific to the gluzincins. For example, valine has been tried with success as a substituting amino acid, but other amino acids such as hydrophobic, and preferably aliphatic, amino acids may be equivalent.

Example II: Enzymatic assay

A peptide consisting of, for example, 10 amino acid residues spanning the cleavage site of PTHrP107-139 is synthesized by solid-phase peptide synthesis and used as a substrate for PHEX. The cleavage site is determined by assaying the enzymatic reaction products with a mass spectrometer equipped with a liquid sample inlet port, as found with LC-MS instruments, with the separation achieved in-line or off-line. This decapeptide (10 µg) is incubated in the presence of purified secPHEX (1-10 µg total protein), at 37°C for 60 min in MES pH 6.5. The reaction is terminated by the addition of TFA to a final concentration of 0.1%. Metabolites are analyzed using a C-18 µ-Bondapack column (Waters). For example, metabolites may be resolved with a 45 min linear gradient of 0-40% acetonitrile in

0.1% trifluoroacetic acid at a rate of 1.0 ml/min. The eluted peptides are detected by monitoring their absorbance at 214 and 254 nm. The decapeptide should be cleaved into two shorter peptides that will be eluted at different retention times. The peak fractions corresponding to these two peptides are collected and their molecular mass is determined by mass spectrometry to identify the position of the cleavage site. Once validated as a substrate for PHEX, the synthetic peptide described here above may be modified such as to incorporate amino acid derivatives bearing either fluorescent groups, chromogenic groups or radioactive atoms. These peptides derivatives are then used to construct fast, sensitive and robust enzymatic assays for further quantifying and characterizing PHEX in tissue extracts, as described in Example III.

Example III: Screening for quenched-fluorescent substrate

The peptide identified in Example II is used to design and synthesize internally quenched fluorescent peptide substrates for PHEX. Small peptide libraries are prepared with a fluorophore at one extremity and a quencher group at the other (Meldal, 1998). The substrate can be identified using a strategy described in (Apletalina et al., 1998). For each hexapeptide library, the identity of one residue at one position remains constant while the rest is randomized (for a total of $6 \times 20 = 120$ individual libraries). Each library is comprised of 3.2 million different members and is identified both by the position of the constant residue along the hexapeptide, and its identity. A purified preparation of PHEX enzyme is added to each library and the fluorescence is recorded. The data is organized to identify the libraries producing the most fluorescence for each position along the hexapeptide. This arrangement suggests the identity of important residues at each position along the hexapeptide. Hexapeptides representing the best suggestions are prepared and tested in a similar fashion. From this set, the hexapeptide with the best fluorescence is selected. This assay can be useful for setting up a high throughput screening method for identifying inhibitors in combinatorial libraries of compounds.

Example IV: Uses of recombinant PHEX protein in therapeutic applications

The murine Hyp model reproduces the characteristics of human X-linked hypophosphatemia (XLH), an inherited disease causing renal loss of phosphate (Pi), severe rickets and osteomalacia. The presence of renal phosphate wasting due to a mutation in the PHEX gene suggests that this endopeptidase degrades a yet unidentified phosphaturic hormone, referred to as phosphatonin (Kumar, 1997). To test this hypothesis directly, primary mouse proximal tubule cell cultures (MPTC), expressing normal features of proximal tubule cells are prepared. The presence of 10% Hyp mouse serum in HAMF12/DMEM media (1 mM Pi) for the last 48 hours of culture of MPTC was previously found to reduce Pi uptake by $45.7 \pm 3.9\%$, as compared with normal mouse serum, in a dose- and time-dependent manner (Lajeunesse et al., 1996). If defects in the PHEX gene in Hyp mouse osteoblasts are responsible for the release and/or the modification of a factor that can reach the circulation and inhibit renal phosphate re-absorption, it should be possible to abolish the effect of the Hyp mouse serum on Pi uptake by pretreating the serum with a purified preparation of PHEX. The effect of PHEX (1-10 μg of purified recombinant secPHEX) on Hyp mouse serum is then monitored by measuring phosphate uptake by MPTC cells. Control experiments include incubating the serum samples under similar conditions, but with heat or acid inactivated PHEX. If PHEX treatment is found to restore normal phosphate uptake, recombinant soluble PHEX might thus be used as a therapeutic agent for restoring normal phosphate levels, first in animal models (such as the Hyp mouse) and then in patients with pathological states characterized with X-linked hypophosphatemic rickets.

Patients suffering from oncogenic hypophosphatemic osteomalacia, a rare disorder, display abnormalities similar to those found with X-linked hypophosphatemic rickets patients. Therefore, normophosphatemia in these patients may be re-established with the administration of soluble PHEX enzyme.

Example V: Production and use of PHEX antibodies

As shown in the present work, knowledge of PHEX cDNA sequences can be used to raise specific antibodies. For example, regions of lesser homology between the peptidases (amino acid residues 121 to 294) can be used to synthesize peptides whose sequences are deduced from the translation of the cDNAs. Alternatively, bacterially- expressed fragments of the cDNAs fused to GST, for example, may be purified and injected into rabbits or mice for polyclonal or monoclonal antibody production. These antibodies or derived "diagnostic reagents", which usually comprise labelled antibodies, can be used to:

- Identify by immunohistochemistry the peptidergic pathways in which the peptidases are functioning;
- Study the physiopathology of PHEX by immunoblotting or immunohistochemistry on samples of biological fluids or biopsies;
- Set up high through put screening assays to identify PHEX inhibitors. This can be done, for example, by using the antibodies to attach the PHEX to a solid support;
- Purify PHEX with said antibodies by immunoprecipitation or affinity chromatography by identifying antibodies capable of selectively binding to PHEX in one set of conditions and releasing it in another set of conditions, typically involving a large pH or salt concentration change without denaturing PHEX;
- Identify antibodies that block PHEX activity and use them as therapeutic agents. Blocking antibodies can be identified by adding antisera or ascites fluid to an *in vitro* enzymatic assay as described in Example II and looking for inhibition of PHEX activity. Blocking antibodies may then be injected in normal and disease model animals to test for *in vivo* effects.

Example VI: Alternative methods for producing recombinant soluble PHEX enzymes

As shown above, recombinant active PHEX enzymes can be obtained by expression of PHEX cDNAs in mammalian cells. From past experience with another member of the family, neprilysin (Devault et al., 1988; Fossiez et al., 1992; Ellefsen, 1999), expression can also be performed in other expression systems after cloning of PHEX cDNA in appropriate expression vectors. These expression systems may include the baculovirus/insect cells or larvae system and the *Pichia pastoris*-based yeast system. Production of recombinant PHEX enzymes includes the production of naturally occurring membrane bound or soluble forms of the protein, or genetically- engineered soluble forms of the enzyme. The latter can be obtained by substituting the cytosolic and trans-membrane domain by a cleavable signal peptide, such as that of proopiomelanocortin, as done previously (Lemay et al., 1989a) or by transforming by genetic manipulations the non-cleavable signal peptide membrane anchor domain into a cleavable signal peptide, as done previously (Lemire et al., 1997a) or by fusion of the ectodomain of PHEX enzyme to the amino-terminal domain (from the initiator methionine to amino acid residue 300) of naturally occurring soluble NEP-like enzymes such as NL-1, as done in other work.

EXAMPLE VII Identification of inhibitors

Inhibitors can be identified from synthetic libraries, biota extracts, the current literature and from rationally- designed inhibitors using X-ray crystallography and substituent activity relationships. Each molecule or extract fraction is tested for inhibitory activity using the enzymatic test described above. The molecule responsible for the largest inhibition is further tested to determine its pharmacological and toxicological properties following known procedures.

In vitro inhibition of enzymatic PHEX degradation can be screened using any of several art-recognized *in vitro* models. In these models, a peptide ("substrate") is exposed to the PHEX enzyme. The substrate may either be a bone related peptide, a peptide known to be cleaved by any other family member or another peptidic substrate susceptible to degradation by the PHEX enzyme. Degradation

of the peptide results in liberation of specific metabolites. The amount of metabolite liberated (or peptide maintained) can be monitored to determine the degree of degradation of the substrate by the enzyme. That is, PHEX enzyme inhibitors can be tested to determine their propensity to reduce the amount of metabolite liberated by degradation of a particular substrate by a particular enzyme.


These *in vitro* models generally consist of a test sample (containing a PHEX enzyme inhibitor and a peptidic substrate) and a control sample (containing the substrate with no PHEX inhibitor). Each sample is exposed to a particular inhibitor, and the samples are then compared to determine whether significantly more metabolite (or less substrate) is present in the control sample than in the test sample. If there is significantly more metabolite (or less substrate) in the control sample than the test sample, the test compound is an inhibitor of the enzyme(s) present. One such method is described above.

There is an extensive literature available on Zn metallopeptidases (Roques 1982a, Roques 1982b, Ondetti 1984, Roques 1985, Roques 1986, Chipkin 1986, Thorsett 1987, Rich 1990, Vallee 1990) as potent inhibitors of Neprilysin (NEP). Among the many known functional groups able to coordinate the Zn^{++} cation, the thiol, carboxyl, hydroxamyl and phosphoryl groups have all been used with success in the development of ACE and NEP inhibitors. All such molecules that display inhibitory activity of the PHEX enzyme (PHEX inhibitors) are encompassed by the present invention.

As indicated above, PHEX is a member of a family of enzymes that share similar properties, such as their sensitivity to the same inhibitor and their ability to process the same substrates. Numerous PHEX enzyme inhibitors and methods for their preparation are described in the literature and are useful in the methods of the present invention. Such inhibitors are described in the following references, all of which are incorporated herein by reference: U.S. Pat. No. 4,380,535, to Sarantakis, issued Apr. 19, 1983; U.S. Pat. No. 4,423,242, to Wilkinson et al.,

issued Dec. 27, 1983; U.S. Pat. No. 4,474,795, to Greenberg et al., issued Oct. 2, 1984; U.S. Pat. No. 4,504,492, to Wilkinson et al., issued Mar. 12, 1985; U.S. Pat. No. 4,513,009, to Roques et al., issued Apr. 23, 1985; U.S. Pat. No. 4,514,391, to Gordon et al., issued Apr. 30, 1985; U.S. Pat. No. 4,528,296, to Vecchiotti et al., issued Jul. 9, 1985; U.S. Pat. No. 4,552,866, to Delaney et al., issued Nov. 12, 1985; U.S. Pat. No. 4,567,198, to Delevallee et al., issued Jan. 28, 1986; U.S. Pat. No. 4,610,816, to Berger, issued Sep. 9, 1986; U.S. Pat. No. 4,611,002, to Ondetti, issued Sep. 9, 1986; U.S. Pat. No. 4,618,708, to Roques et al., issued Oct. 21, 1986; U.S. Pat. No. 4,636,522, to Gordon, issued Jan. 13, 1987; U.S. Pat. No. 4,670,541, to Delaney et al., issued Jun. 2, 1987; U.S. Pat. No. 4,681,960, to Kakimoto et al., issued Jul. 21, 1987; U.S. Pat. No. 4,721,726, to Berger, issued Jan. 26, 1988; U.S. Pat. No. 4,722,810, to Delaney et al., issued Feb. 2, 1988; U.S. Pat. No. 4,939,261, to Ksander, issued Jul. 3, 1990; U.S. Pat. No. 5,096,925, to Ksander, issued Mar. 17, 1992; U.S. Pat. No. 5,098,934, to Vever et al., issued Mar. 24, 1992; U.S. Statutory Invention Registration No. 11642, Floyd et al., published Jun. 6, 1989; United Kingdom Patent Publication 8111322, Wilkinson, published Nov. 4, 1981; United Kingdom Patent Publication, Wilkinson et al., published Apr. 7, 1983; European Patent Publication 161,769, Delaney et al., published Nov. 21, 1985; European Patent Publication 341,081, Kawamura et al., published Nov. 8, 1989; European Patent Publication 474,553, Shibahara et al., published Mar. 11, 1992; PCT Patent Publication 92/03410, Neustadt et al., published Mar. 5, 1992; Fournie-Zaluski et al., 'Differential Recognition of 'Enkephalinase' and Angiotensin-Converting Enzyme by New Carboxylalkyl Inhibitors', 31 Life & L 2947-2954 (1982); Mimura et al., "A Novel Class of Enkephalinase Inhibitors Containing a C-Terminal Sulfo Group", 35.!. Med. Chem. 602—608 (1992).


Preferred PHEX enzyme inhibitors useful in the methods of the present invention have the general structure of formula (I):



wherein

- (1) L is $-S-R^3$ or $-C(=O)-R^4$ where R^3 is hydrogen or $-C(=O)-R^5$, where R^5 is lower alkyl; and where R^4 is hydroxy or $-NHOH$;
 - (2) R^1 is hydrogen, lower alkyl, aryl, arylalkyl ;
 - (3) A is $-C(=O)-$, $-NH-C(=O)-$, or $-N(R^6)$, where R^6 is hydrogen or lower alkyl;
 - (4) B is $-NH-$, $-O-$, $-S-$, or $-C(=O)-$
 - (5) R^2 is hydrogen, lower alkyl, aryl, arylalkyl (preferably phenylmethyl);
 - (6) X is $-C(=O)-NH-R^7$ or $-C(=O)-O-R^7$ where R^7 is hydrogen, lower alkyl, phenyl, or arylalkyl;
 - (7) m is from 0 to about 2;
 - (8) n is 0 or 1 (preferably 0); and
 - (9) p is from 0 to about 4 (preferably 0 or 1);
- and pharmaceutically-acceptable salts thereof.

Other preferred PHEX inhibitors have the general structure (II):



wherein:

- (1) L, R^1 , A, m, and n are as described in formula (I);
 - (2) Z is $-NH-$, $-O-$, $-S-$, $-C(=O)-$, or nil; and
 - (3) R^7 is a carbocyclic ring or a heterocyclic ring; preferably benzenesulfonic acid, pyridyl, or morpholinyl;
- and pharmaceutically-acceptable salts thereof.

Other preferred PHEX inhibitors, as described in U.S. Pat. No. 4,721,726, to Berger, issued Jan. 26, 1988, have the general structural formula (III):




and the racemates, enantiomers and diastereoisomers thereof, as well as the pharmaceutically acceptable salts thereof wherein:

R_1 is alkyl having from 1 to 6 carbon atoms, adamantylmethyl, cycloalkylmethyl having from 4 to 8 carbon atoms or $A-X_m-C_nH_{2n}$ wherein X is oxygen or sulfur, A is phenyl which may be substituted with the group, Y, where Y is

halogen, hydroxy, trifluoromethyl, alkoxy having from 1 to 6 carbon atoms, alkyl having from 1 to 6 carbon atoms, 2- and 3-furanyl, 2- and 3-thienyl, or phenyl (which may be substituted with halogen, hydroxy, trifluoromethyl, alkoxy having from 1 to 6 carbon atoms or alkyl having from 1 to 6 carbon atoms) benzyl (the phenyl ring of which may be substituted with the group, Y, as defined herein), 1- and 2-naphthyl, 2- and 3-furanyl or 2- and 3-thienyl; m is 0 or 1 and n is 0, 1, 2, 3, or 4;

R_2 and R_8 may be the same or different and are hydroxy, alkoxy having from 1 to 8 carbon atoms, $B-X_m-C_nH_{2n}-O-$ wherein B is phenyl (which may be substituted with the group, Y, as defined herein) or 1- and 2-naphthyl, X, m, and n are as defined herein provided that when $n=0$, $m=0$, $-OCH_2OCO-$ alkyl having from 3 to 8 carbon atoms, $-OCH_2CO-$ Phenyl (the phenyl ring of which may be substituted with the group, Y, as defined herein), 1-glyceryl,



wherein R_7 is hydrogen, alkyl having from 1 to 6 carbon atoms, or phenyl which may be substituted with the group, Y, as defined herein, and R_8 hydrogen or alkyl having from 1 to 6 carbon atoms;

R_2 may also be $-NR_7R_8$ wherein R_7 and R_8 are as defined herein;


R_3 is alkyl having from 1 to 6 carbon atoms, cycloalkylmethyl having from 4 to 8 carbon atoms, 2- and 3-thienylmethyl, 2- and 3-furanylmethyl, 1- and 2-naphthylmethyl, or benzyl the phenyl ring of which may be substituted with the group, Y, as defined herein;

R_4 is $D-C_nH_{2n}O_m-$ wherein D is hydrogen, alkyl having from 1 to 4 carbon atoms or phenyl which may be substituted with the group, Z, wherein Z is halogen, hydroxy, trifluoromethyl, alkoxy having from 1 to 6 carbon atoms, or alkyl having from 1 to 6 carbon atoms; m and n are as defined herein;

R_4 may also be $-NR_5COR_7$ (wherein R_5 and R_7 are defined herein), and $-NR_5CO_2R_9$ (wherein R_5 is defined herein and R_9 is alkyl having from 1 to 6 carbon atoms or phenyl which may be substituted with the group Y, as defined herein) provided that p is 1 or 2;

R_5 is hydrogen or alkyl having from 1 to 6 carbon atoms; and p is 0, 1 or 2.

Other preferred PHEX enzyme inhibitors, as described by Mimura et al., "A Novel Class of Enkephalinase Inhibitors Containing a C-Terminal Sulfo Group", 351. *Med. Chem.* 602-608, have the general structure (IV):



wherein:

R_1 is selected from phenyl, p-methylphenyl, p-methoxyphenyl, p-fluorophenyl, p-trifluoromethylphenyl, p-nitrophenyl, p-dimethylaminophenyl, p-phenylphenyl, phenylethyl, 1-naphthyl, 3-pyridyl, 1,2-benzisoxazol-3-yl, or 1-methylethyl;

R_2 is selected from hydrogen or cyclopropyl; and

R_3 is selected from CR_2 , CH_2-CH_2 , $CH_2-CH_2-CH_2$, $CH(CH_3)$, $CH(CH_2CH(CH_3)_2)$, o-phenyl, m-phenyl, p-phenyl, p-phenylmethyl, and 1,4-naphthylene.

Particularly preferred PHEX enzyme inhibitors useful in the methods of the present invention include (DL-3-mercapto-2-benzylpropanoyl)-glycine; 1-(DL-3-mercapto-2-methylpropanoyl)-L-proline; 2-benzyl-3-(N-hydroxycarboxamido)-propanoyl-L-alanine; 2-benzyl-3-(N-hydroxycarboxamido)-propanoyl-L-phenylalanine; (\pm)-N-(2-acetylthio)methyl-1-oxo-3-phenylpropyl glycine benzyl ester; N-morpholinyl-2-phenylmethyl-3-mercaptopropanamide; alpha-(mercaptomethyl)-N-(4-pyridyl)benzenepropanamide; N-[2-benzyl-3-(N-hydroxycarboxamido)-propanoyl]-3-amino-4-phenylbutyric acid; N-[(R,S)-2-benzyl-3-[(S)(2-amino-4-methylthio)butyldithio]-1-oxopropyl]-L-Phe-benzyl ester; N-(2-benzyl-3-mercaptopropanoyl) metanilic acid; and N-[(R,S)-2-carboxy-3-phenyl-propanoyl]-L-Leu.

The inhibitor with the best distribution, pharmacological action combined with low toxicity will be selected for drug manufacturing. Pharmaceutically acceptable formulation of the inhibitor or its acceptable salt will be prepared by mixing with known excipients to produce tablets, capsules or injectable solutions. Between 1 and 500 mg of the drug is administered to the patients.

EXAMPLE VIII Therapeutic uses

The present invention also provides methods of treatment for hyperphosphatemia, including its most frequent manifestations, secondary hyperparathyroidism and renal osteodystrophy. The method comprises the administration of a PHEX inhibitor that induces a reduction in circulating phosphate, thus reducing, or preferably preventing, hyperphosphatemia and the appearance of its most frequent consequences.

As indicated above, PHEX is member of a family of metalloproteases that shares similar properties including, as indicated above, their sensitivity to the same inhibitor and their capability of processing the same substrates. Numerous NEP-like enzyme inhibitors, and methods for their preparation, are described in the literature and are useful in the methods of the present invention.

The PHEX inhibitors that show inhibitory activity are administered to rats weighing about 250g at a dose of 1mg/kg. The control group consists of another group of rats where the same vehicle is administered without the PHEX inhibitor. Serum and urine are obtained from the test animals using standard methods. Phosphate concentration in serum and in urine is then measured by standard methods. PHEX inhibitors capable of inducing a change in phosphate concentration are said to be hypophosphatemic. Such compounds are the preferred "hypophosphatemic PHEX inhibitors" for the purpose of treating hyperphosphatemic patients.

The "least effective dose" is the minimum dose that is required to induce a significant reduction in serum phosphate or PTH concentration. Preferably, the therapy will be initiated with such a dose. The treatment preferably involves the administration of a "hypophosphatemic PHEX inhibitor" for a period of time sufficient to achieve a reduction in phosphate or PTH blood concentration or both (here and after the blood parameters). Preferably, the net reduction is about 25% of the difference between the patient value and that of the normal population or,

more preferably, at least about 50% of the difference between the patient's value and that of the normal population. The specific period of time sufficient to achieve this reduction in the subject blood parameters may depend on a variety of factors. Such factors include, for example, the specific hypophosphatemic inhibitor employed, the amount administered, the age and gender of the subject, the specific disorder to be treated, concomitant therapies employed (if any), the general physical health of the subject (including the presence of other disorders), the severity of the disease in the individual, and the nutritional habits of the individual.

According to the methods of this invention, "administering" refers to any method which, in sound medical practice, delivers the hypophosphatemic inhibitor used in this invention to the subject to be treated in such a manner so as to be effective in achieving a reduction in the blood parameters. The hypophosphatemic PHEX enzyme inhibitor may be administered by any of a variety of known methods of administration, e.g., orally, dermatomucosally (for example, dermally, sublingually, intranasally, and rectally), parenterally (for example, by subcutaneous injection, intramuscular injection, intra-articular injection, intravenous injection), and by inhalation. Thus, specific modes of administration include, for example, oral, transdermal, mucosal, sublingual, intramuscular, intravenous, intraperitoneal, subcutaneous administration, and topical application. A preferred mode for delivering the hypophosphatemic PHEX enzyme inhibitors is orally, for as long and as frequently as medically required. The period and frequency is adjusted after regular measurement of serum phosphate, PTH and vitamin D metabolites.

Thus, a preferred method of this invention comprises the steps of performing a diagnostic on a human subject for the detection of hyperphosphatemia, including its most frequent manifestations, secondary hyperparathyroidism and renal osteodystrophy and, upon obtaining a positive result from said diagnostic, administering the hypophosphatemic PHEX enzyme inhibitor according to the methods of this invention. Suitable diagnostics for the

detection of hyperphosphatemia, including its most frequent manifestations, secondary hyperparathyroidism and renal osteodystrophy, are well known in the art. Such methods include the measurement of the blood, serum, plasma or urinary phosphate or the measurement of the blood, serum or plasma PTH.

EXAMPLE IX Dosage forms

The hypophosphatemic PHEX enzyme inhibitors described herein may be administered in any of a variety of pharmaceutically acceptable compositions. Such compositions may comprise an active and a pharmaceutically acceptable carrier. Accordingly, for example, compositions for administering the hypophosphatemic PHEX enzyme inhibitor comprise:

- (a) From about 1.0 mg to about 1 000.0 mg of a hypophosphatemic PHEX enzyme inhibitor; and
- (b) A pharmaceutically acceptable carrier.

Pharmaceutically-acceptable carriers include solid or liquid filler diluents or encapsulating substances, and mixtures thereof, that are suitable for administration to a human or lower animal. The term "compatible", as used herein, means that the components of the pharmaceutical composition are capable of being co-mingled with the hypophosphatemic PHEX enzyme inhibitor, and with each other, in a manner such that there is no interaction, which would substantially reduce the pharmaceutical efficacy of the pharmaceutical composition under ordinary use situations. Pharmaceutically acceptable carriers must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the humans or lower animals being treated.

Some examples of the substances which can serve as pharmaceutical carriers are: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such-as sodium

carboxymethylcellulose, ethylcellulose, cellulose acetate; powdered tragacanth; malt; gelatin; talc; stearic acid; magnesium stearate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerin, sorbitol, mannitol, and polyethylene glycol; agar; alginic acid; pyrogen-free water; isotonic saline; phosphate buffer solutions; wetting agents and lubricants such as sodium lauryl sulfate; coloring agents; flavoring agents; and preservatives. Other compatible pharmaceutical additives and hypophosphatemic PHEX enzyme inhibitor may be included in the pharmaceutically acceptable carrier for use in the compositions of the present invention.

The choice of a pharmaceutically-acceptable carrier to be used in conjunction with the active substance is determined by the way the active substance is to be administered. If the active is to be injected, the preferred pharmaceutical carrier is sterile water, physiological saline, or mixtures thereof. The pH of such parenteral composition is preferably adjusted to about 7.4. Suitable pharmaceutically acceptable carriers for topical application include those known in the art for use in creams, gels, tapes, patches, and similar topical delivery means.

The pharmaceutically- acceptable carrier employed in conjunction with the hypophosphatemic PHEX enzyme inhibitor is used at a concentration sufficient to provide a practical size to dosage relationship. The pharmaceutically-acceptable carriers, in total, may comprise from about 0.1% to about 99.9% by weight of the pharmaceutical compositions of the present invention, preferably from about 5% to about 80%, and most preferably from about 10% to about 50%.

As indicated, the preferred method of administering hypophosphatemic PHEX enzyme inhibitor is dependent upon the class of active being administered. For the hypophosphatemic PHEX inhibitors, the preferred method of administration is orally, in a unit-dosage form (i.e., a dosage form containing an amount of active

suitable for administration in one single dose, according to sound medical practice).

Preferred unit dosage forms include tablets, capsules, suspensions, and solutions, comprising a safe and effective amount of active. Pharmaceutically-acceptable carriers suitable for the preparation of unit dosage forms for oral administration are well known in the art. Their selection will depend on secondary considerations like taste, cost, shelf stability, which are not critical for the purposes of the present invention, and can be made without difficulty by a person skilled in the art. Preferably, oral unit dosage forms of the hypophosphatemic PHEX enzyme inhibitor comprise from about 1.0 mg to about 1000 mg of the inhibitor.

The present invention is intended to further encompass the following: (1) diagnostic kits for detecting the presence or amount of PHEX in a sample; (2) a method for detecting the presence or amount of PHEX in a sample; (3) devices for purifying PHEX or mutants thereof; (4) devices for screening PHEX ligands; and (5) a method for obtaining a PHEX ligand. More particularly, the diagnostic kits comprise antibodies and/or a soluble PHEX enzyme. Antibodies against PHEX may be used in devices for purifying PHEX, and PHEX or mutants thereof may be used in devices for screening PHEX ligands. Though not described herein, the more general aspects concerning the operability of the diagnostic kits and devices included in the present invention are known in the art and readily available.

The method for detecting the presence or amount of PHEX comprises the following steps:

- contacting a sample containing PHEX with an antibody in conditions such that immune complexes can form; and
- detecting the immune complexes as an indication of the presence or amount of PHEX in the sample.

The method for obtaining a PHEX ligand comprises the following steps:

- contacting a sample containing one or more molecules with a PHEX mutant enzyme in conditions such that binding of the molecules with PHEX can occur;
- detecting the binding of the molecules with PHEX as an indication of the presence of a PHEX ligand in the sample; and
- selecting the PHEX ligand.

Although not described in detail, the particulars relating to experimental conditions for carrying out the methods described above are within the purview of those skilled in the art and readily appreciable by them.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

REFERENCE LIST

- Almaden Y, Canalejo A, Hernandez A, Ballesteros E, García-Navarro S, Torres A and Rodriguez M (1996) Direct effect of phosphorus on PTH secretion from the whole rat parathyroid glands in vitro. *J Bone Miner Res* Jul 11:7 970-6
- Apletalina, E., Appel, J., Lamango, N.S., Houghten, R.A., and Lindberg, I. (1998). Identification of inhibitors of prohormone convertases 1 and 2 using a peptide combinatorial library. *J.Biol.Chem.* 273, 26589-26595.
- Beck, L., Soumounou, Y., Martel, J., Krishnamurthy, G., Gauthier, C., Goodyer, C.G., and Tenenhouse, H.S. (1997). Pex/PEX tissue distribution and evidence for a deletion in the 3' region of the Pex gene in X-linked hypophosphatemic mice. *J.Clin.Invest.* 99, 1200-1209.
- Blais, A., Bissonnette, P., and Berteloot, A. (1987). Common characteristics for Na⁺-dependent sugar transport in Caco- 2 cells and human fetal colon. *J.Membr.Biol.* 99, 113-125.
- Borle AB and Clark I (1981) Effects of phosphate-induced hyperparathyroidism and parathyroidectomy on rat kidney calcium in vivo. *Am J Physiol* Aug 241:2 E136-41
- Chipkin, R.E. : Inhibitors of enkephalinase : the next generation of analgesics. *Drugs Future* 11 : 593-606, 1986.
- Crine, P., Dion, N., and Boileau, G. (1997). Endopeptidase-24.11. In *Cell-Surface Peptidases in Health and Disease*. A.J. Kenny and C.M. Boustead, eds. (Oxford: BIOS Scientific Publishers), pp. 79-98.
- Demeter JG, De Jong SA, Oslapas R, Ernst K, Hessel P, Jarosz H, Smith M, Nayyar R, Lawrence AM and Paloyan E (1991) High phosphate diet-induced primary hyperparathyroidism: an animal model. *Surgery* Dec 110:6 1053-60.
- Devault, A., Lazure, C., Nault, C., Le Moual, H., Seidah, N.G., Chrétien, M., Kahn, P., Powell, J., Mallet, J., Beaumont, A., Roques, B.P., Crine, P., and Boileau, G. (1987). Amino acid sequence of rabbit kidney neutral endopeptidase 24.11 (enkephalinase) deduced from a complementary DNA. *EMBO J.* 6, 1317-1322.
- Devault, A., Nault, C., Zollinger, M., Fournié-Zaluski, M.-C., Roques, B.P., Crine, P., and Boileau, G. (1988). Expression of neutral endopeptidase (enkephalinase) in heterologous COS- I cells. Characterization of the recombinant enzyme and evidence for a glutamic acid residue at the active site. *J.Biol.Chem.* 263, 4033-4040.

- Du, L., Desbarats, M., Viel, J., Glorieux, F.H., Cawthorn, C., and Ecarot, B. (1996). cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone. *Genomics* 36, 22-28.
- Ecarot, B., Glorieux, F.H., Desbarats, M., Travers, R., and Labelle, L. (1992). Effect of dietary phosphate deprivation and supplementation of recipient mice on bone formation by transplanted cells from normal and X-linked hypophosphatemic mice. *J.Bone Miner.Res.* 7, 523-530.
- Ellefsen (1999). Immobilization d'une forme chimérique soluble de l'endopeptidase neutre - 24.11 sur un support chromatographique et mise au point d'un test de liaison. Mémoire de maîtrise Université de Montréal.
- Fossiez, F., Lemay, G., Labonté, N., Parmentier-Lesage, F., Boileau, G., and Crine, P. (1992). Secretion of a functional soluble form of neutral endopeptidase- 24.11 from a baculovirus-infected insect cell line. *Biochem.J.* 284, 53-59.
- Francis, F., Hennig, S., Korn, B., Reinhardt, R., De Jong, P., Poustka, A., Lehrach, H., Rowe, P.S.N., Goulding, J.N., Summerfield, T., Mountford, R., Read, A.P., Popowska, E., Pronicka, E., Davies, K.E., O'Riordan, J.L.H., Econs, M.J., Nesbitt, T., Drezner, M.K., Oudet, C., Pannetier, S., Hanauer, A., Strom, T.M., and Meindl, A. (1995). A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. *Nature Genet.* 11, 130-136.
- Grieff, M., Mumm, S., Waeltz, P., Mazzarella, R., Whyte, M.P., Thakker, R.V., and Schlessinger, D. (1997). Expression and cloning of the human X-linked hypophosphatemia gene cDNA. *Biochemical & Biophysical Research Communications* 231, 635-639.
- Guo, R. and Quarles, L.D. (1997). Cloning and sequencing of human PEX from a bone cDNA library: Evidence for its developmental stage-specific regulation in osteoblasts. *J.Bone Miner.Res.* 12, 1009-1017.
- Howell, S., Lanctôt, C., Cailler, F., and Crine, P. (1995). Addition of a glycosylphosphatidylinositol anchor to a soluble form of neutral endopeptidase reestablishes its apical targeting in LLC-PKI cells. *The Biochemical Society Meeting* 657, 41-41.(Abstract)
- Kates DM, Sherrard DJ and Andress DL (1997) *Am J Kidney Dis* Dec 30:6 809-13
- Korth, P., Egidy, G., Parnot, C., LeMoullec, J.M., Corvol, P., and Pinet, F. (1997). Construction, expression and characterization of a soluble form of human endothelin-converting-enzyme-1. *FEBS Lett.* 417, 365-370.

- Kumar, R. (1997). Phosphatonin--a new phosphatoretic hormone? (lessons from tumourinduced osteomalacia and X-linked hypophosphataemia) [editorial]. *Nephrol.Dial.Transplant.* 12, 11-13.
- Lajeunesse, D., Meyer, R.A.J., and Hamel, L. (1996). Direct demonstration of a humorally-mediated inhibition of renal phosphate transport in the Hyp mouse. *Kidney Int.* 50, 1531 - 1538.
- Lemay, G., Waksman, G., Roques, B.P., Crine, P., and Boileau, G. (1989). Fusion of a cleavable signal peptide to the ectodomain of neutral endopeptidase (EC 3.4.24.11) results in the secretion of an active enzyme in COS- 1 cells. *J.Biol.Chem.* 264, 15620- 15623.
- Lemire, I., Lazure, C., Crine, P., and Boileau, G. (1997). Secretion of a type II integral membrane protein induced by mutation of the transmembrane segment. *Biochem.J.* 322, 335-342.
- Lipman, M.L., Panda, D., Bennett, H.P., Henderson, J.E., Shane, E., Shen, Y.N., Goltzman, D., and Karaplis, A.C. (1998). Cloning of human PEX cDNA Expression, subcellular localization, and endopeptidase activity. *J.Biol.Chem.* 273, 13729-13737.
- Meldal, M. (1998). Intramolecular fluorescence-quenched substrate libraries. *Methods Mol.Biol.* 87:65-74, 65-74.
- Nelson, A.E., Mason, R.S., and Robinson, B.G. (1997). The PEX gene: not a simple answer for X-linked hypophosphataemic rickets and oncogenic osteomalacia. *Mol.Cell.Endocrinol.* 132, 1-5.
- Meyer, RA Jr, Gray RW and Meyer MH. 1980. Abnormal vitamin D metabolism in the X-linked hypophosphatemic mouse. *Endocrinology*, 107:1577-1581.
- Ondetti, M.A., and Cushman, D.W. : Angiotensin-converting enzyme inhibitors : biochemical properties and biological action. *Crit. Rev. Biochem.* 16 : 381-411, 1984.
- Rasmussen, H. and Tenenhouse, H.S. (1995). Mendelian hypophosphatemias. In *The metabolic and Molecular Basis of Inherited disease*. C.L. Scriver, A.L. Beaudet, W.S. Sly, and D. Valle, eds. (New York: McGraw Hill), pp. 3717-3745.
- Rich, D.H. : Peptidase inhibitors. In *comprehensive Medicinal Chemistry. The Rational Design, Mechanistic Study and Therapeutic Application of Chemical Compounds*, ed. by P.G. Sammes and J.B. Taylor, Vol. 2, p. 391, Pergamon Press, New York, 1990.
- Rifas, L., Dawson, L.L., Halstead, L.R., Roberts, M., and Avioli, L.V. (1994). Phosphate transport in osteoblasts from normal and X-linked hypophosphatemic mice. *Calcif.Tissue Int.* 54, 505-510.

- Roques, B.P., Fournié-Zaluski, M.C., Florentin, D., Waksman, G., Sassi, A., Chaillet, P., Collado, H., and Constantin, J. : New enkephalinase inhibitors as probes to differentiate "enkephalinase" and angiotensin-converting-enzyme active sites. *Life Sci.* 31 : 1749-1752, 1982a.
- Roques, B.P., Fournié-Zaluski, M.C., Gacel, G., Lucas-Soroca, E., David, M., Schwartz, J.C., Malfroy, B., Llorens, C., Swerts, J.P., Lecomte, J.M., Meunier, J.C., Moisand, C., Morgat, J.L., and Maigret, B. : Synthèse et études physicochimiques et biologiques de ligands spécifiques des récepteurs enkephalinergiques mu et delta et d'inhibiteurs du système de dégradation des enképhalines endogènes. *Acta Chim. Ther.* 9 : 211-240, 1982b.
- Roques, B.P., and Fournié-Zaluski, M.C. : A new way to antinociceptive compounds through rational design of enkephalin degrading enzymes inhibitors. In *Proceedings of the International Symposium on Medicinal Chemistry* ed. by R. Dalhborn and J.L.G. Nilsson, pp. 134-146, Swedish Pharmaceutical Press, Stockholm, Sweden, 1985.
- Roques, B.P., and Fournié-Zaluski, M.C. : Enkephalin degrading enzyme inhibitors : a physiological way to new analgesics and psychoactive agents. *Natl. Inst. Drug Abuse Res. Monogr. Ser.* 70 : 128-154, 1986.
- Ruchon, A.F., Marcinkiewicz, M., Siegfried, G., Tenenhouse, H.S., DesGroseillers, L., Crine, P., and Boileau, G. (1998). Pex mRNA is localized in developing mouse osteoblasts and odontoblasts. *J.Histochem.Cytochem.* 46, 459-468.
- Strom, T.M., Francis, F., Lorenz, B., Boddrich, A., Econs, M.J., Lehrach, H., and Meitinger, T. (1997). Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia. *Hum.Mol.Genet.* 6, 165- 171.
- Tenenhouse HS, Yip A and Jones G., 1988, Increased renal catabolism of 1,25-dihydroxyvitamin D3 in murine X-linked hypophosphatemic rickets. *J. Clin. Invest.* 81:461-465.
- Tenenhouse HS and Jones G. 1990, Abnormal regulation of renal vitamin D catabolism by dietary phosphate in murine X-linked hypophosphatemic rickets. *J. Clin. Invest.* 85, 1450-1455.
- Tenenhouse HS et al, *Am J. Physiol* 1998, Oct 275:4 Pt 2 F527-34
- Thorsett, E.D. and Wyvratt, M.J. : Inhibition of zinc peptidases that hydrolyse neuropeptides. In *Neuropeptides and their Peptidases*, ed. by A.J. Turner, pp. 229-292, Harwood, Chichester, UK, 1987.
- Turner, A.J. (1997). Endothelin-converting enzymes. In *Cell-surface peptidases in health and disease*. A.J. Kenny and C.M. Boustead, eds. (Oxford, UK: BIOS Scientific Publishers Ltd.), pp. 137-153.

- Turner, A.J. and Tazawa, K. (1997b). Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. *FASEB J.* 11, 355-364.
- Vallee, B.L., and Auld, D.S. : Zinc coordinating function and structure of zinc enzymes and other proteins. *Biochemistry* 29 : 5647-5659, 1990.
- Xiao, Z.S., Crenshaw, M., Guo, R., Nesbitt, T., Drezner, M.K., and Quarles, L.D. (1998). Intrinsic mineralization defect in Hyp mouse osteoblasts. *Am.J.Physiol.Endocrinol.Metab.* 275, E700-E708
- Yang, X.F., Crine, P., and Boileau, G. (1995). The nature of topogenic sequences determines the transport competence of topological mutants of neutral endopeptidase-24.11. *Biochem.J.* 312, 99-105.

We claim:

1. A soluble purified human PHEX enzyme and variants thereof
2. A mutant of the enzyme of claim 1, which is inactive but retains binding capacity to a ligand molecule to PHEX.
3. A mutant as defined in claim 2 essentially consisting of PHEX enzyme having the glutamic acid residue at position 582 is mutated.
4. A mutant as defined in claim 2 essentially consisting of PHEX enzyme having the glutamic acid residue at position 582 substituted with a hydrophobic amino acid residue.
5. A mutant as defined in claim 2 essentially consisting of PHEX enzyme having the glutamic acid residue at position 582 substituted with a valine residue.
6. A nucleic acid which comprises a truncated PHEX gene sequence encoding PHEX membrane-anchor domain modified to include a cleavable signal peptide and PHEX C-terminal ectodomain is active or inactive.
7. A nucleic acid as defined in claim 6, wherein said cleavable signal peptide is pro-opiomelanocortin signal peptide.
8. A recombinant vector comprising the nucleic acid of claim 6 or 7.
9. A recombinant vector as defined in claim 8, which is an expression vector.
10. A recombinant host comprising the recombinant vector of claim 8.


11. A recombinant host comprising the recombinant vector of claim 9.
12. A method for producing a soluble PHEX enzyme or an inactive mutant thereof, which comprises the steps of:
 - allowing the recombinant host of claim 11 to express said nucleic acid, and
 - recovering the soluble PHEX enzyme or mutant thereof as a secretion product of said recombinant host.
13. An antigenic composition, which comprises the enzyme of any one of claims 1 to 5.
14. An antibody raised against the enzyme of any one of claims 1 to 5, or fragment thereof capable of binding to PHEX.
15. The antibody of claim 14, wherein said fragment extends from residue 121 to residue 294 of the amino acid sequence of PHEX.
16. An antibody as defined in claim 14, which is a monoclonal antibody.
17. An antibody as defined in claim 15, which is a monoclonal antibody.
18. The antibody of claim 16, which is a PHEX neutralizing antibody.
19. A hybridoma producing the antibody of any one of claims 16 to 18.
20. A composition comprising the enzyme of claim 1 or the nucleic acid of claim 6 and a pharmaceutically acceptable carrier.
21. A composition comprising the enzyme of any one of claims 2 to 5 and a pharmaceutically acceptable carrier.

22. A composition comprising the antibody of any one of claims 14 to 18 and a pharmaceutically acceptable carrier.
23. A diagnostic reagent for detecting the presence or amount of PHEX, comprising the antibody of any one of claims 14 to 18.
24. A diagnostic kit for detecting the presence or amount of PHEX comprising the antibody of any one of claims 14 to 18.
25. The diagnostic kit of claim 24, which further comprises a soluble PHEX enzyme.
26. A method for detecting the presence or an amount of PHEX in a sample, which comprises the steps of:
 - contacting said sample with the antibody of any of any one of claims 14 to 18 in conditions such that the immune complex can form; and
 - detecting the immune complexes as an indication of the presence or amount of PHEX in said sample.
27. A device for purifying PHEX or a mutant thereof which comprises the antibody of any one of claims 14 to 18.
28. A device for screening PHEX ligands, which comprises the soluble PHEX enzyme or a mutant thereof as defined in any one of claims 1 to 5.
29. The device of claim 27, wherein said antibody is fixed onto a solid support.

30. The device of claim 28, wherein said PHEX enzyme or mutant is fixed onto a solid support.
31. The device of claim 30, wherein said PHEX enzyme or mutant is fixed onto the solid support through its binding to an anti-PHEX antibody itself fixed onto said solid support.
32. The device of claim 30, wherein said PHEX enzyme or mutant is fixed onto the solid support through a C-terminal amino acid extension ending with a residue or group capable of coupling PHEX to the solid support.
33. A method for obtaining a PHEX ligand which comprising the steps of:
- contacting a sample containing one or more molecules with a PHEX mutant enzyme as defined in any one of claims 2 to 5 in conditions such that binding of said one or more molecules with PHEX can occur;
 - detecting said binding as an indication of the presence of a PHEX ligand in said sample; and
 - selecting said PHEX ligand.
34. The method of claim 33, wherein said ligand is a PHEX inhibitor or substrate.
35. A method for evaluating PHEX activity in a sample which comprises the steps of contacting the sample with PTHrP107-139 in substantially phosphate-free conditions and observing the apparition of a cleavage product of PTHrP107-139 as an indication of PHEX activity in the sample.
36. The method of claim 35 which further comprises a step of comparing said PHEX activity in the sample with the activity of the PHEX enzyme of claim 1 as a positive control.

37. A method for evaluating the activity of a molecule for its capacity of being a substrate of PHEX comprising the steps of:
- contacting said molecule with the PHEX enzyme of claim 1 in substantially phosphate-free conditions; and
 - observing a cleavage product of said molecule as an indication that the molecule is a PHEX substrate.
38. The method of claim 37, which further comprises the step of comparing said molecule with PTHrP107-139 as a positive control.
39. A method for evaluating the activity of a molecule for its capacity of being an inhibitor of PHEX comprising the steps of:
- contacting said molecule with PTHrP107-139 and the PHEX enzyme of claim 1 in substantially phosphate-free conditions; and
 - observing an inhibition of the formation of a cleavage product of PTHrP107-139 as an indication that the molecule is a PHEX inhibitor.
40. A kit for executing the method of any one of claims 35 to 39.

1/8



FESE-1AVGGTLVLGTILFLVSQGLLS 1VLTVIAQQTTTFLVSQGLLS 2VLTVIAQQTT SQGLLS 3FESE-1B

2/8



1	MEAETGSSVE	TGKKANRGTR	I ALVVEVGGT	I VLGTILFLV	SQGLSLQAK	QEYCLKPECI
61	EAATAILSKV	NLSVDPDNE	FRFACDGNIS	NNPIPEDMPS	YGVYPWLRHN	VDLKLKELLE
1121	KSISRRTDTE	AIQKAKILYS	SCMNEKAIEK	ADAKPLHLIL	RHSPFRWPVL	ESNIGPEGVW
1181	SERKFSLLOT	LATERGQYSN	SVFIRLYVSP	DDKASNEHIL	KLDQATLSLA	VREDYLDNST
2241	EAKSYRDALY	KFMVDTAVLL	GANSRAEHD	MKSVLRLLEIK	IAEIMIPHEN	RTSEAMYNKM
3301	NISELSAMIP	QEDWLGYIKK	VIDTRLYPHL	KDISPSENVV	VRVPQYFKDL	FRILGSEKKK
3361	TIANYLVWRM	VYSRIPNLSR	RFQYRWLEFS	RVIQGTTL	PQWDKCVNFI	ESALPYVVGK
4421	MFVDVYFQED	KKEMMEELVE	GVRWAFIDML	EKENEWMDAG	TKRKAKEKAR	AVLAKVGYPE
4481	FIMNDTHVNE	DLKAIKFSEA	DYFCGNVLQTR	KYLAQSDFFW	LRKAVPKTEW	FTNPTTVNAF
5541	YASTNQIRF	PAGELQKPEF	WGTEYPRSL	YGAIGVIVGH	EFTHGFDNNG	RKYDKNGNLD
6601	PWSTESEEEK	FKEKTKCMIN	QYSNYYYWKKK	GLNVKGKRTL	GENIADNGGL	REAFRAYRKW
6661	INDRRQGLEE	PLLPGITFTN	NQLFFLSYAH	VRCNSYRPEA	AREQVQIGAH	SPPQFRVNGA
7721	ISNSEEFQKA	FNCPPNSTMN	RGMDSCRLW			

File



3/8






4/8




5/8




6/8




7/8



7-6F




7-6E




7-6D

8/8



HH-6H



GG-6G

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 August 2000 (31.08.2000)


PCT

(10) International Publication Number
WO 00/50580 A3

- (51) International Patent Classification⁷: C12N 9/64, 15/57, 5/10, C07K 16/40, A61K 38/48, 48/00, 39/395, G01N 33/53
- (74) Agents: DUBUC, Jean, H. et al.; Goudreau Gage Dubuc, The Stock Exchange Tower, Suite 3400, 800 Place Victoria, Montreal, Quebec H4Z 1E9 (CA).
- (21) International Application Number: PCT/CA00/00201
- (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 24 February 2000 (24.02.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 2,262,056 24 February 1999 (24.02.1999) CA
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): UNIVERSITE DE MONTREAL [CA/CA]; 2900 boulevard Edouard-Montpetit, Montreal, Quebec H3C 3J7 (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): CRINE, Philippe [CA/CA]; 28 Avenue Claude-Champagne, Outremont, Quebec H2V 2X1 (CA). BOILEAU, Guy [CA/CA]; 7645 Malherbe, Brossard, Quebec J4Y 1E6 (CA).
- Published:
— with international search report
- (88) Date of publication of the international search report:
2 August 2001

[Continued on next page]

(54) Title: COMPOSITION, METHODS AND REAGENTS FOR THE SYNTHESIS OF A SOLUBLE FORM OF HUMAN PHEX



(57) Abstract: This invention relates to a soluble form of PHEX, PHEX being a type II integral membrane glycoprotein. This enzyme is the gene product of a phosphate-regulating gene with homologies to endopeptidases on the X chromosome. To produce a soluble form of PHEX, the transmembrane anchor domain has been modified to encode a signal peptidase coding sequence. The soluble PHEX therefore comprises the active ectodomain. An inactive mutant of PHEX is also an object of this invention. Both soluble and inactive mutant forms of PHEX can be used to screen ligands to PHEX. These ligands can also be used as substrates or inhibitors of PHEX. PHEX being phosphaturic, an inhibitor thereof will be used to treat phosphaturia and/or hypophosphatemia. On the opposite, a substrate for PHEX or PHEX itself can be used to treat hyperphosphatemia.

WO 00/50580 A3



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/00201

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N9/64 C12N15/57 C12N5/10 C07K16/40 A61K38/48
A61K48/00 A61K39/395 G01N33/53

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, PAJ, WPI Data, MEDLINE, SCISEARCH, BIOTECHNOLOGY ABS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 10078 A (HENDERSON JANET E ;KARAPLIS ANDREW C (CA); LIPMAN MARK L (CA); SHE) 12 March 1998 (1998-03-12) the whole document --- -/--	1-34

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

5 February 2001

Date of mailing of the international search report

20. 2. 01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

ALCONADA RODRIG., A

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>LIPMAN MARK L ET AL: "Cloning of human PEX cDNA: Expression, subcellular localization, and endopeptidase activity" JOURNAL OF BIOLOGICAL CHEMISTRY, US, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 273, no. 22, 29 May 1998 (1998-05-29), pages 13729-13737, XP002134628 ISSN: 0021-9258</p> <p>page 13731, left-hand column, last paragraph -right-hand column, paragraph 4</p> <p>page 13734, left-hand column, paragraph 3</p> <p>-page 13735, right-hand column, paragraph 2</p> <p>figures 2,7,8</p> <p>---</p>	1-13,20, 21,35-40
Y	<p>DEVAULT A ET AL: "EXPRESSION OF NEUTRAL ENDOPEPTIDASE ENKEPHALINASE IN HETEROLOGOUS COS-1 CELLS CHARACTERIZATION OF THE RECOMBINANT ENZYME AND EVIDENCE FOR A GLUTAMIC ACID RESIDUE AT THE ACTIVE SITE" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, no. 8, 1988, pages 4033-4040, XP000930009 ISSN: 0021-9258</p> <p>figures 6,7</p> <p>page 4036, right-hand column, paragraph 2</p> <p>-page 4039, right-hand column, paragraph 1</p> <p>---</p>	2-5, 13-19, 21-34, 37,40
Y	<p>LEMAY G ET AL: "FUSION OF A CLEAVABLE SIGNAL PEPTIDE TO THE ECTODOMAIN OF NEUTRAL ENDOPEPTIDASE EC 3.4.24.11 RESULTS IN THE SECRETION OF AN ACTIVE ENZYME IN COS-1 CELLS" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 264, no. 26, 1989, pages 15620-15623, XP000929927 ISSN: 0021-9258</p> <p>cited in the application</p> <p>page 15621, right-hand column, paragraph 2</p> <p>-page 15622, left-hand column, paragraph 1</p> <p>---</p> <p>-/--</p>	1,6-34, 37,40

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KORTH PETRA ET AL: "Construction, expression and characterization of a soluble form of human endothelin-converting enzyme-1." FEBS LETTERS, vol. 417, no. 3, 17 November 1997 (1997-11-17), pages 365-370, XP002147123 ISSN: 0014-5793 cited in the application figures 1,4 page 367, left-hand column, paragraph 1 -page 369, left-hand column, paragraph 1 ----	1,6-34, 37,40
Y	HELENE A ET AL: "EFFECTS OF MONOCLONAL ANTIBODIES RAISED AGAINST THE COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN ON ENDOPEPTIDASE-24.11 ACTIVITY" BIOCHEMICAL PHARMACOLOGY, vol. 43, no. 4, 1992, pages 809-814, XP000925844 ISSN: 0006-2952 tables 1-3 page 810, left-hand column, paragraph 2 -right-hand column, last paragraph ----	14-19, 22-27,29
Y	FENTON A J ET AL: "Long-term culture of disaggregated rat osteoclasts: Inhibition of bone resorption and reduction of osteoclast-like cell number by calcitonin and PThrP(107-139)." JOURNAL OF CELLULAR PHYSIOLOGY, vol. 155, no. 1, 1993, pages 1-7, XP000979777 ISSN: 0021-9541 figures 2,5 -----	35,36, 38-40

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA 00/00201

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-34, 37 (complete) and 40 (partially)

A soluble form of human PHEX; an inactive form of soluble PHEX which still binds ligands consisting on a mutant having glutamic residue at position 582 mutated to valine; a nucleic acid encoding a soluble PHEX in which the transmembrane anchor has been modified to include a cleavable signal peptide, preferably from pro-opiomelanocortin; recombinant vector and host; a method for producing a recombinant soluble PHEX, an antigenic composition, monoclonal or polyclonal antibodies raised against the soluble PHEX, pharmaceutical compositions containing the nucleic acid, the soluble enzyme and the antibody of the invention; diagnostic reagents and kits comprising the anti-PHEX antibody; a method for detecting the presence of PHEX in a sample using the anti-PHEX antibody; a device to purify PHEX using anti-PHEX antibody in which the antibody is fixed to a solid support ; a device to screen PHEX ligands using the soluble PHEX or a mutant thereof in which the the PHEX molecule is fixed to a solid support; a method to obtain a PHEX ligand; a method for evaluating the activity of a molecule for its capacity of being a substrate of PHEX and a kit to carry out said method.

2. Claims: 35, 36, 38, 39 (complete) and 40 (partially)

A method for evaluating PHEX activity in a sample comprising contacting said sample with PTHrp107-139 and observing the appearance of the cleavage product; said method further comprising comparing said PHEX activity with the activity of the soluble PHEX; a method for evaluating the activity of a molecule for its capacity of being a substrate of PHEX comprising contacting said molecule with soluble PHEX and observing a cleavage product of said molecule as an indication that the molecule is a substrate of PHEX, said method further comprising the step of comparing said molecule with PTHrp107-139 as a positive control; a method for evaluating the activity of a molecule for its capacity of being an inhibitor of PHEX comprising contacting said molecule with PTHrp107-139 and soluble PHEX and observing an inhibition of the formation of a cleavage product of PTHrp107-139; a kit for executing any of the previous methods.

INTERNATIONAL ARCH REPORT

Information on patent family members

International Application No.

PCT/CA 00/00201

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9810078 A	12-03-1998	AU 4107397 A	26-03-1998